[go: up one dir, main page]

WO1998054140A1 - Novel terephthalamide derivatives - Google Patents

Novel terephthalamide derivatives Download PDF

Info

Publication number
WO1998054140A1
WO1998054140A1 PCT/KR1997/000183 KR9700183W WO9854140A1 WO 1998054140 A1 WO1998054140 A1 WO 1998054140A1 KR 9700183 W KR9700183 W KR 9700183W WO 9854140 A1 WO9854140 A1 WO 9854140A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
piperazin
pyridyl
carbonyl
compound
Prior art date
Application number
PCT/KR1997/000183
Other languages
French (fr)
Inventor
Sung Joon Yoon
Yong Ho Chung
Sang Wook Lee
Hyeong Su Sim
Yong Kyun Park
Jong Woo Kim
Yong Huh
Jae In Yoon
Sang Jin Park
Original Assignee
Dongwha Pharmaceutical Ind. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019970020958A external-priority patent/KR19980085016A/en
Priority claimed from KR1019970023289A external-priority patent/KR19990000415A/en
Priority claimed from KR1019970036589A external-priority patent/KR100491100B1/en
Application filed by Dongwha Pharmaceutical Ind. Co., Ltd. filed Critical Dongwha Pharmaceutical Ind. Co., Ltd.
Priority to AU44733/97A priority Critical patent/AU731638B2/en
Publication of WO1998054140A1 publication Critical patent/WO1998054140A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel terephthalamide derivatives and in particular to novel terephthalamide derivatives of the following formula 1, its pharmaceutically acceptable salts as antiviral agents having remarkable inhibitory actions against the proliferation of various viruses including HIV and HBV, and preparing method thereof.
  • Ri and R represent independently one selected from hydrogen atom; phenyl group; benzyl group; C ⁇ C ⁇ alkyl group; substituted C ⁇ C alkyl group in which substituent selected from di(C ⁇ C alkyl)amino, acetylamino group and heterocycles; C ⁇ Cs hydroxyalkyl group; substituted C ⁇ C 4 hydroxyalkyl group in which one or two suitable substituents selected from phenyl, benzyl, C ⁇ C hydroxyalkyl and C ⁇ C 7 alkyl group; C ⁇ C 6 alkoxyalkyl group; di(C 2 ⁇ C6 alkoxy)alkyl group; C2M5 (hydroxyalkoxy)alkyl group; with the proviso that Ri and R do not simultaneously represent hydrogen atom; in case where either Ri or R 2 is hydrogen atom, the stereospecificity of (R)- or (S)-type may be represented; further, Ri and R 2 may be combined with one or two hetero atoms selected from nitrogen, oxygen and
  • HBV hepatitis B virus
  • nucleoside compounds which have been mainly developed as an anti-AIDS(Acquired Immune Deficiency Syndrome) agent, are effective HBN inhibitors J. Org. Chem., 1992, Vol. 57, 2217].
  • these nucleoside compounds as effective drugs against viral hepatitis B have proven to be undesirable due to high costs of drugs, adverse reactions and toxic effects.
  • HIN human immunodeficiency virus
  • HBN is a virus different from HIN but during proliferation, they have common replication courses, i. e., a reverse transcription step and the resulting R A template of R ⁇ A-D ⁇ A hybrid is degraded. Since terephthalamide derivatives according to the present invention of the formula 1, have mechanism to inhibit such proliferation course, it may be developed as effective inhibitor against the proliferation of various viruses including HBN and HIN.
  • an object of the present invention is to provide novel terephthalamide derivatives of the following formula 1, its pharmaceutically acceptable salts as antiviral agents having remarkable inhibitory activities against the proliferation of various viruses including HIV and HBV, and preparing method thereof.
  • the present invention is related to novel terephthalamide derivatives of the following formula 1 and its pharmaceutically acceptable salts.
  • Ri, R 2 and R3 are the same as defined above, respectively.
  • the preferred terephthalamide derivatives of the formula 1 according to the present invention are as follows:
  • one is hydrogen atom and the other is an C ⁇ C 3 alkoxy C ⁇ C alkyl group; di(C 2 ⁇ Cs alkoxy) C ⁇ C alkyl group; l,3-dioxolan-2-yl-methyl group; tetrahydrofuran-2-yl-methyl group; 2- (morpholin-4-yl) ethyl group; 3-(morpholin-4-yl)propyl group; 2-(piperidin-l- yl)ethyl group; di(C ⁇ C 3 alkyl) amino Q-C3 alkyl group; 2-(acetylamino)ethyl group; 2-hydroxyethyl group; or substituted 2-hydroxyethyl group with one or two suitable substituents selected from phenyl group, benzyl group, C ⁇ C 3 hydroxyalkyl group and C ⁇ Cs alkyl group,
  • one is C ⁇ C 3 alkyl group and the other is di(C ⁇ C3 alkoxy) C ⁇ C3 alkyl group; l,3-dioxolan-2-yl-methyl group; tetrahydrofuran-2-yl-methyl group; 2-(morpholin-4-yl)ethyl group; 3- (morpholin-4-yl)propyl group; 2-(piperidin-l-yl)ethyl group; 2-hydroxyethyl group; di(C ⁇ C3 alkyl)amino C ⁇ C3 alkyl group; or 2-(acetylamino)ethyl group,
  • Ri and R are simultaneously C1M3 alkyl group, hydroxyethyl group or 2-hydroxypropyl group, and
  • Ri and R 2 are combined with one or two hetero atoms selected from nitrogen, oxygen and sulfur to form heterocycles such as morpholine, thiomorpholine, pyrrolidine, piperidine or piperazine ring, in particularly in the case of piperazine ring it is selectively substituted with hydrogen atom, C ⁇ C5 alkyl group, C 3 ⁇ C 6 cycloalkyl group, C 2 ⁇ Cs hydroxyalkyl group, C 2 ⁇ C dihydroxyalkyl group, C3--C5 (hydroxyalkoxy)alkyl group, C ⁇ C3 alkyl-substituted O- hydroxyalkyl group, (2R)-3-hydroxy-2- methylpropyl group or (2S)-3-hydroxy-2-methylpropyl group.
  • heterocycles such as morpholine, thiomorpholine, pyrrolidine, piperidine or piperazine ring
  • it is selectively substituted with hydrogen atom, C ⁇ C5 alkyl group, C 3 ⁇ C 6
  • the more preferred terephthalamide derivatives of the formula 1 according to the present invention are as follows:
  • Ri is 2-hydroxyethyl group
  • R 2 is hydrogen atom, methyl, ethyl or isopropyl group
  • Ri and R 2 are simultaneously 2-hydroxyethyl, 2- hydroxypropyl, ethyl or isopropyl group
  • R is a substituted 2- hydroxyethyl group, showing (R)- or (S)-type of stereospecificity, in which a substituent in particular such as methyl, ethyl, isopropyl, phenyl, benzyl or hydroxymethyl group at 1- or 2-position, or substituted 2-hydroxyethyl group in which two substituents in particular such as methyl, ethyl or hydroxymethyl group at 1-position,
  • Ri is hydrogen atom or 2-methoxyethyl group
  • R is 2- methoxyethyl, 3-methoxypropyl, 3-ethoxypropyl or 3-isopropoxypropyl group
  • R ⁇ is hydrogen atom or methyl group
  • R 2 is 2,2- dimethoxyethyl, 2,2-diethoxyethyl, l,3-dioxolan-2-yl-methyl, tetrahydrofuran- 2-yl-methyl, 2-(morpholin-4-yl)ethyl, 3-(morpholin-4-yl)propyl or 2-(piperidin- l-yl)ethyl group
  • Ri is hydrogen atom, methyl or ethyl group
  • R is 2-
  • Ri and R 2 are forming heterocycles such as morpholine, thiomorpholine, pyrrolidine, piperidine or piperazine ring, together with nitrogen atom,
  • Ri and R2 are forming a piperazine ring
  • nitrogen atom at 4-position is selectively substituted with methyl, ethyl, isopropyl, cyclopropyl, cyclopentyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3- dihydroxypropyl, 2,2-dimethyl-3-hydroxypropyl, (2R)-3-hydroxy-2- methylpropyl, (2S)-3-hydroxy-2-methylpropyl or 2-(2-hydroxyethoxy)ethyl group, and
  • both Ri and R 2 are the same as defined above, while R3 is an isopropyl group.
  • the typical examples of terephthalamide derivatives of the above formula 1 are as follows: l-[N-(2-Hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 1), 1 - [N-(3-Hy droxy propy l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 2),
  • terephthalamide derivatives of the above formula 1 according to the present invention may form its pharmaceutically acceptable acid-addition salts with acid in accordance with some ordinary methods in the art to which the present invention pertains.
  • the acid-addition salts may include inorganic acids(e. g., hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid) or organic acids(e. g., formic acid, acetic acid, propionic acid, oxalic acid, citric acid, maleic acid or methanesulfonic acid). Since terephthalamide derivatives of the above formula 1 according to the present invention has potent effects against the proliferation of HBV and HIV, it may be used as a clinically useful anti-hepatitis B agent and anti-AIDS agent.
  • the present invention includes pharmaceutical compositions containing the terephthalamide derivatives of the above formula 1, and its pharmaceutically acceptable salts as active ingredients.
  • compositions of the present invention When pharmaceutical compositions of the present invention is intended for clinical application, it may be formulated into several dosage forms containing some exipients commonly used in pharmaceutical field; for example, oral preparations(e. g., tablets, capsules, troches, solutions or suspensions); injectables(e. g., injectable solution or suspension, or injectable dry powder which can be immediately used by adding water for injection prior to injection); topical preparations(e. g., ointments, creams or solutions).
  • the vehicles used for pharmaceutical compositions of the present invention are common types available m the pharmaceutical field, which include; binders, lubricants, disintegrants, excipients, solubilizers, diluents, stabilizers, suspending agent, pigments, flavors, etc.
  • the pharmaceutical preparations may be administered orally or parenterally(e. g., intravenously, subcutaneously, intraperitoneally or topically). Some drugs may be formulated as an enteric coated tablet when they are unstable in gastric condition.
  • the clinical dose of terephthalamide derivatives of the above formula 1 in patients may be appropriately determined according to therapeutic efficacy and bioavailability of active ingredients in the body, their metabolism and excretion rate, and age, sex, stage of target diseases of the patient but generally, the daily dose of adult should be given at 10 ⁇ 500 mg, preferably at 50 ⁇ 300 mg. Therefore, when pharmaceutical compositions of the present invention is prepared as an unit dosage form, the formulation of each unit should be made available so as to contain 10 ⁇ 500 mg of terephthalamide derivatives of the above formula 1, preferably 50 ⁇ 300 mg, in consideration of the above mentioned effective dose. These preparations may be administered at certain intervals of several times(preferably one to 6 times) in accordance with medical doctor or pharmacist's direction.
  • the present invention also includes a process of preparing terephthalamide derivatives of the present invention of the above formula 1.
  • terephthalamide derivatives may be prepared by the following reaction schemes 1, 2 and 3.
  • reaction scheme 1 is a schematic diagram showing a process of preparing terephthalamide derivatives of the above formula 1 as a desired product by reacting a compound of the formula 2 and some amine compounds.
  • Ri, R 2 and R3 are the same as defined in the above, respectively.
  • terephthalic acid derivatives of the formula 2 is reacted with some acid chloride(e. g., pivaloyl chloride) to form an acid anhydride with good reactivity; then, the intermediate is further reacted with amine compounds of the formula 3, to obtain terephthalamide derivatives of the above formula 1 as a desired product.
  • Such reaction is completed at 0 ⁇ 30 ° C within 6 hours in the presence of the general tertiary organic bases such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, N- methylpiperidine, 4-dimethylaminopyridine, N,N-dimethylaniline, 2,6-lutidine or pyridine.
  • a single solvent or co-solvent selected from chloroform, methylene chloride, acetonitrile, tetrahydrofuran, dioxane, dioxolane, N,N-dimethylformamide, N,N-dimethylacetamide and N- methylpyrrolidone.
  • reaction scheme 2 Another direct process of preparing terephthalamide derivatives of the above formula 1 as a desired p r oduct via reaction between a compound of the following formula 4, a precursor of a compound of formula 2 used in the above reaction scheme 1 and some amine compounds and its preparing process is illustrated in the following reaction scheme 2. Namely, this method has an advantage of shortening one processing step of starting material. [Reaction scheme 2]
  • Ri, R 2 and R3 are the same as defined in the above, respectively.
  • reaction scheme 2 the reaction is carried out under direct nucleophilic substitution between amine compounds of the formula 3 and methyl ester group of terephthalic acid ester derivatives of the formula 4.
  • the nucleophilic substitution reaction is completed at 40 ⁇ 90 ° C within 20 hours using some alcoholic solvents(e. g., methanol, ethanol, propanol, isopropanol or butanol) or polar organic solvents(e. g., acetonitrile, N,N- dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone).
  • some alcoholic solvents e. g., methanol, ethanol, propanol, isopropanol or butanol
  • polar organic solvents e. g., acetonitrile, N,N- dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone
  • amine compounds of the formula 3 used in the reaction scheme 1 and 2 are reagents intended for introducing the substituents Ri and
  • amine compounds selected by required substituents, may be easily used by a person having ordinary skill in the art to which the this invention pertains.
  • Ri and R 2 combine with nitrogen atom to form a piperazine ring
  • a desired product can be prepared by the following reaction scheme 3 in addition to the reaction scheme 1 and 2.
  • R3 is the same as defined in the formula 1;
  • R represents hydrogen atom, Ci-Cs alkyl group, C3 ⁇ Cs cycloalkyl group, Ci-Cs hydroxyalkyl group, C 2 ⁇ Cs dihydroxyalkyl group, C 2 ⁇ Cs (hy droxy alkoxy )alkyl group, Ci ⁇ C3 alkyl-substituted C ⁇ C hydroxyalkyl group, (2R)-3-hydroxy-2-methylpropyl or (2S)-3-hydroxy-2-methylpropyl group;
  • X represents halogen atom
  • Reaction is carried out in such a manner that terephthalic acid derivatives of the formula 2 as a starting material of the reaction scheme 1, is reacted with some acid chloride(e. g., pivaloyl chloride) to form an acid anhydride with good reactivity; then, the intermediate is further reacted with piperazine of the formula 5, to obtain terephthalamide derivatives of the above mentioned formula la as a desired product.
  • acid chloride e. g., pivaloyl chloride
  • polar solvents such as methanol, ethanol, isopropanol, butanol, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide or N- methylpyrrolidone.
  • the reaction is quantitatively carried out at 50 ⁇ 110 ° C within 30 hours in the presence of tertiary organic bases such as triethylamine, N-methy lmorpholine, N-methylpiperidine or 2,6-lutidine.
  • reaction scheme 4 each compound used as a starting material of the formula 2 or 4, respectively, can be prepared by the following reaction scheme 4 prior to use.
  • R3 is the same as defined in the formula 1.
  • mono-methyl terephthalate of the formula 9 is reacted with some acid chloride(e. g., pivaloyl chloride) to form an acid anhydride with good reactivity; then, the intermediate is further reacted with pyridylpiperazine derivative of the formula 8, to obtain terephthalic acid ester derivative including nitropyridyl group of the above mentioned formula 10.
  • acid chloride e. g., pivaloyl chloride
  • pyridylpiperazine derivative of the formula 8 is further reacted with pyridylpiperazine derivative of the formula 8, to obtain terephthalic acid ester derivative including nitropyridyl group of the above mentioned formula 10.
  • Such reaction is completed at 0 ⁇ 30 ° C within 5 hours in the presence of tertiary organic bases.
  • the main solvents used for this reaction include some non- polar solvents such as methylene chloride, chloroform, etc..
  • the compound of the formula 10 is reduced by catalytic hydrogenation to give the compound including aminopyridyl group of the formula 11.
  • Such reduction may be well carried out under high-pressure condition using hydrogen gas in the presence of small amounts of activated metal catalysts such as Raney-nickel or palladium on activated carbon, being widely used in the reductive reaction.
  • activated metal catalysts such as Raney-nickel or palladium on activated carbon
  • Various solvents such as methanol, ethanol, methylene chloride, chloroform or ethyl acetate may be used for this reaction.
  • the compound including aminopyridyl group of the formula 11 are under reductive alkylation with acetone or acetaldehyde in the presence of a selective reducing agent such as sodium cyanoborohydride under acidic conditions to form terephthalic acid ester derivatives including isopropylamino or ethylamino group, expressed by the formula 4.
  • a selective reducing agent such as sodium cyanoborohydride under acidic conditions to form terephthalic acid ester derivatives including isopropylamino or ethylamino group, expressed by the formula 4.
  • Such reaction may be well carried out in the presence of some organic acids such as acetic acid and in general, alcoholic solvents such as methanol or ethanol are used.
  • terephthalic acid ester derivatives so formed and expressed by the formula 4 are hydrolyzed, terephthalic acid derivatives of the formula 2 is obtained and the solvents used for this reaction include a co-solvent where water is added to lower alcohols such as methanol, ethanol or isopropanol.
  • the hydrolysis is completed at below 40 ° C within 3 hours.
  • Example 3 1 - [N-(4-Hy droxy buty l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 1. Yield: 77 % m.p. : 131 ⁇ 132 ° C ⁇ -NMR(CDC1 3 ), ppm : ⁇ 1.21(d, 6H), 3.02(s, 3H), 3.11(m, 4H), 3.53(m, 3H),
  • Example 8 l-[N-(2-Hydroxyethyl)-N-(l-methylethyl)carbamoyl]-4-[l-[3- 25 (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 10. Yield: 76 % m.p. : 71 ⁇ 72 ° C
  • Example 12 l-[N,N-Bis(2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- py ridy 1] piperazin-4-y 1-carbony 1] benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 10. Yield : 83 % m.p. : 161 ⁇ 162 ° C
  • the desired compound was obtained by the same synthetic method as described in the Example 1. Yield : 80 % m.p. : 78 ⁇ 80 ° C
  • Example 14 l-[N,N-Bis(l-methylethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- py r idy 1] piper azin-4-y 1-carbony 1] benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 1.
  • Example 17 l-[N-Ethyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(ethylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
  • Example 18 l-[4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl- carbony 1] benzoy 1] piperazine 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid
  • Example 19 1 - [4- [1 - [3-(Isopropy lamino)-2-py ridy 1] piper azin-4-yl- carbonyl]benzoyl]-4-methylpiperazine 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid
  • Example 20 4-Ethyl-l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbony 1] benzoy 1] piperazine
  • the desired compound was obtained by the same synthetic method as described in the Example 19. Yield: 85 % m.p. : 130 ⁇ 131 TJ ⁇ -NMR(CDC1 3 ), ppm : ⁇ 1.07(t, 3H), 1.20(d, 6H), 2.51 (m, 6H), 3.05(m, 4H),
  • Example 21 4-Cyclopentyl-l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4- y 1-carbony 1] benzoy 1] piperazine l-[4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoyl]piperazine (0.5 g) was dissolved in acetonitrile (25 ml) and then, N-methylmorpholine (0.17 ml) and cyclop ntyl bromide (0.3 ml) were added. The solution was heated to 65 ⁇ 75 ° C and stirred for 20 hours.
  • Example 23 4-(3-Hydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine l-[4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoyl]piperazine (0.5 g) was dissolved in anhydrous ethanol (25 ml) and then, triethylamine (0.3 mi) and 3-bromo-l-propanol (0.5 g) were added. The solution was heated to reflux for 12 hours. The solvent was concentrated under reduced pressure and then, the residue was dissolved in chloroform (50 ml), and the solution was washed with water twice. Water
  • Example 24 4-[(2R)-3-Hydroxy-2-methylpropyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
  • the desired compound was obtained by the same synthetic method as described in the Example 23. Yield: 75 % ⁇ -NMR(CDC1 3 ), ppm : ⁇ 1.01(d, 3H), 1.20(d, 6H), 2.00(m, IH), 2.50(m, 2H),
  • Example 25 4-[(2S)-3-Hydroxy-2-methylpropyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
  • the desired compound was obtained by the same synthetic method as described in the Example 23. Yield: 72 % ⁇ -NMR(CDC1 3 ), ppm : ⁇ 1.02(d, 3H), 1.21(d, 6H), 2.01(m, IH), 2.50(m, 2H),
  • the desired compound was obtained by the same synthetic method as described in the Example 23. Yield: 80 %
  • Example 27 4-(2,3-Dihydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2- py ridyl] piperazin-4-y 1-carbony l]benzoyl] piperazine
  • Example 28 4-[2-(2-Hydroxyethoxy)ethyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
  • the desired compound was obtained by the same synthetic method as described in the Example 19. Yield: 80 % m.p. : 92 ⁇ 93 ° C ⁇ -NMR(CDC1 3 ), ppm : ⁇ 1.21(d, 6H), 2.55(m, 4H), 3.09(m, 4H), 3.52(m, 5H),
  • the desired compound was obtained by the same synthetic method as described in the Example 31. Yield : 75 %
  • Example 33 l-[N-[(lS)-2-Hydroxy-l-(l-methylethyl)ethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using (S)-(+)-2-amino-3-methyl-l-butanol. Then, the product was recrystallized using ethanol and isopropyl ether to give a desired compound. Yield: 80 % m.p. : 82 ⁇ 83 ° C
  • Example 34 l-[N-[(lR)-2-Hydroxy-l-(l-methylethyl)ethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 33. Yield: 72 % m.p. : 86 ⁇ 88 ° C
  • Example 35 l-[N-[(lS)-l-Ethyl-2-hydroxyethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • Example 38 l-[N-[(lS)-l-(Cyclohexylmethyl)-2-hydroxyethyl]carbamoyl]-4-[l- [3-(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 39. Yield: 75 %
  • Example 43 1 - [N- [(2S)-2-Hy droxy propyl] carbamoy 1] -4- [1 - [3-(isopropy lamino)- 15 2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 43.
  • Example 46 l-[N,N-Bis(2-methoxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
  • N,N-Diisopropylethylamine (0.8 ml) and bis(2-methoxyethyl)amine (0.6 g) were added in order, the solution was stirred at 0 ⁇ 5 ° C for 2 hours and heated slowly to 20 - 25 ° C and stirred for 30 minutes.
  • the reaction mixture was washed with water twice and with aqueous 5% sodium bicarbonate. Then, the solvent was dried over anhydrous sodium sulfate and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and further recrystallized using ethyl acetate and ether. The recrystallized product was filtered and dried to give
  • the desired compound was obtained by the same synthetic method as described in the Example 45. Yield: 75 %
  • Example 49 l-[N-(2,2-Diethoxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
  • synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using 2,2-diethoxyethylamine. Then, the product was recrystallized using ethanol and isopropyl ether to give the desired compound. Yield : 76 %
  • Example 50 l-[N-[(l,3-Dioxolan-2-yl)methyl]-N-methylcarbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 46. Yield: 81 % m.p. : 102 ⁇ 104 ° C
  • the desired compound was obtained by the same synthetic method as described in the Example 51. Yield: 77 %
  • the desired compound was obtained by the same synthetic method as described in the Example 51. Yield: 79 % ⁇ -NMR(CDC1 3 ), ppm : ⁇ 1.21(d, 6H), 1.61(m, IH), 1.93(m, 2H), 2.03(m, IH),
  • Example 54 4-[l-[3-(Isopropylamino)-2-pyridyl]pi ⁇ erazin-4-yl-carbonyl]-l- (morpholin-4-yl-carbonyl)benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 54. Yield: 76 % m.p. : 163 ⁇ 164 ° C
  • Example 56 4- [1 - [3-(Isopropy lamino)-2-py ridy 1] piperazin-4-y 1-carbony 1] -1 - [N- [2-(morpholin-4-yl)ethyl]carbamoyl]benzene 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid methyl ester (1.2 g) was dissolved in a co-solvent of ethanol (10 ml) and acetonitrile (20 ml), and 4-(2-aminoethyl)morpholine (0.82 g) was added. The reaction mixture was heated to reflux for 15 hours and cooled.
  • Example 58 4- [1 - [3-(Isopropy lamino)-2-py r idy 1] piperazin-4-y 1-carbony 1] -1 - [N- [2-(piperidin-l-yl)ethyl]carbamoyl]benzene
  • Example 60 l-[N-[2-(Dimethylamino)ethyl]-N-methylcarbamoyl]-4-[l-[3- 20 (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
  • the desired compound was obtained by the same synthetic method as described in the Example 60. Yield: 74 %
  • Example 62 l-[N-[2-(Diethylamino)ethyl]carbamoyl]-4-[l-[3-(isopropylamino)- 15 2-py ridyl] piperazin-4-y 1-carbony ljbenzene
  • the inventiors have established a method of measuring the reverse transcriptase activity of HBN polymerase in vitro.
  • the fundamental principle is the same as the ELISA method, and after reacting the substrate with biotin- and DIG-modified nucleotide, a method of recognizing the polymerized substrate as anti-DIG antibody with peroxidase was used. 20/ I of HBV polymerase, 20/ ⁇ C of reaction mixture and 20//4. of test compound were mixed and reacted at 14 - 30 ° C for 18 - 24 hours. Then, the inhibitory effect of test compound against reverse trascriptase activity in the HBV polymerase was examined, compared with the results of control tests without the test compound. The inhibitory activity of each test compound is shown in the following Table 1.
  • E.coli NM 522 was transformed by the expression vector pMRH respectively and the transformants were cultured in LB medium at 37 ° C, overnight. These growing cultures were diluted 1 : 100, inoculated into a glucose rich medium and incubated until OD600 reached 0.5. Then IPTG
  • the above cultured broth was centrifuged for 10 minutes at 3,000 rpm and the cell pellet was washed with 10 ml of TNE column buffer (10 mN Tris-Cl, pH 8.0, 200 mM NaCl, 1 mM EDTA), and resuspended in 10 ml of TNE column buffer.
  • the cells were freezed and thawed -i times repeatedly, and then disrupted by sonication for 10 seconds 3 times.
  • the crude extract prepared in the above process was centrifuged for 30 minutes at 13,000 rpm, 4 ° C and the supernatant was separated. The above process was repeated 2 times and then the supernatant passed the amylose resin.
  • the resin was washed by using column buffer with 50 times of resin volume, and the RNase H domain was eluted by using buffer containing 10 mM maltose.
  • the RNase H domain produced from the expression vector pMRH was purified by using histidine tag affinity column, because RNase H has a histidine tag at the C-terminus.
  • the resin (Ni-NT A, QIAGEN) used in the histidine tag affinity column was activated by using sonication buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride) and 4 - 5 ml of the activated resin was charged in the glass tube whose diameter was about 1 cm.
  • the protein sample obtained from above description passed the resin at the 0.1 ml/ min flow rate and the column was washed by using washing buffer with the 100 - 200 times volume of protein sample (50 mM sodium phosphate, pH 6.0, 300 mM sodium chloride, 10% glycerol).
  • the recombinant protein was eluted by washing the column with concentration gradient of 0.01 - 0.5 M imidazole.
  • the active RNase H domain was separated from the histidine tag affinity column at 30 mM concentration of imidazole.
  • RNase H domain was mixed with 50% glycerol for storage at -20 ° C after the removal of imidazole from it and employed for the screening of HBV inhibitors. 2) Preparation of the substrate of the RNase H enzyme
  • RNA/ DNA complex which can be used as a substrate of the RNase H enzyme was prepared by performing in vitro transcription with E coli M.
  • the compound(l) according to the present invention and its pharmaceutically acceptable salts are effective as active ingredients of inhibiting the proliferation of various viruses including HBV and HIV in that without any cytotoxicity.
  • the RNase H activity was measured by using recombinant Rnase H enzyme and radiolabled RNA/ DNA hybrid. In order to measure the
  • RNase H activity 1 g of RNase H enzyme and test compound were mixed with buffer solution containing 40 mM Tris-Cl (pH 8.0), 4 mM magnesium chloride, 40 mM potassium chloride and 2 mM DTT. The mixture was pretreated on ice for 10 minutes. After pretreatment is completed,
  • RNA/ DNA hybrid was added to incubate at 37 ° C for 3 hours. After the reaction was stopped, 7.5 M ammonium acetate in a volume of 1/2 and ethanol in a 3-fold volume were added. The above reaction mixture was incubated at -20 ° C for more than 2 hours and centrifuged for 15 minutes at 4 ° C, 13,000 rpm. The supernatant was obtained and the radioactive signal of supernatant was measured by scintillation counter.
  • the inhibitory activity in vitro was measured using a non-radioactive reverse transcriptase assay Kit (Boehringer Mannheim).
  • cytotoxicity test was carried out using HepG2 cells in vitro.
  • terephthalamide derivatives of the above formula 1 according to the present invention, and its pharmaceutically acceptable salts proven not to have cytotoxicity with CCso ⁇ 200 ⁇ M.
  • the compounds of the above formula 1 according to the present invention, and its pharmaceutically acceptable salts are effective as active ingredients of inhibiting the proliferation of various viruses including HBV and HIV in that without any cytotoxicity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel terephthalamide derivatives and in particular to novel terephthalamide derivatives of formula (I), its pharamaceutically acceptable salts as antiviral agents having remarkable inhibitory actions against the proliferation of various viruses including HIV and HBV, and preparing method thereof, wherein: R1, R2 and R3 are the same as defined in the detailed description of the present invention.

Description

NOVEL TEREPHTHALAMIDE DERIVATIVES
BACKGROUND OF THE INVENTION Field of the Invention
The present invention relates to novel terephthalamide derivatives and in particular to novel terephthalamide derivatives of the following formula 1, its pharmaceutically acceptable salts as antiviral agents having remarkable inhibitory actions against the proliferation of various viruses including HIV and HBV, and preparing method thereof.
Figure imgf000003_0001
Wherein:
Ri and R represent independently one selected from hydrogen atom; phenyl group; benzyl group; Cι~Cό alkyl group; substituted Cι~C alkyl group in which substituent selected from di(C ~C alkyl)amino, acetylamino group and heterocycles; Cι~Cs hydroxyalkyl group; substituted Cι~C4 hydroxyalkyl group in which one or two suitable substituents selected from phenyl, benzyl, Cι~C hydroxyalkyl and Cι~C7 alkyl group; C ~C6 alkoxyalkyl group; di(C2~C6 alkoxy)alkyl group; C2M5 (hydroxyalkoxy)alkyl group; with the proviso that Ri and R do not simultaneously represent hydrogen atom; in case where either Ri or R2 is hydrogen atom, the stereospecificity of (R)- or (S)-type may be represented; further, Ri and R2 may be combined with one or two hetero atoms selected from nitrogen, oxygen and sulfur to form five or six membered heterocycles, wherein the heterocycles may be substituted with one substituent selected from O-Cs alkyl, C3~C6 cycloalkyl, C3~C5 (hydroxyalkoxy)alkyl, C ~Cs hydroxyalkyl, Cι~C3 alkyl-substituted Cι~C4 hydroxyalkyl, Ci~C dihydroxyalkyl and Cι~C3 alkyl-substituted Cι~C dihydroxyalkyl group; R3 represents Cι~G- alkyl group; further, the above mentioned alkyl group includes straight or branched alkyl group or cycloalkyl group.
Description of the Prior Art Worldwide, about 300 million people are infected with hepatitis B virus(hereinafter referred to as "HBV"), one of the main viruses causing hepatitis and prolonged infection has been associated with cirrhosis and hepatocellular carcinoma. Hitherto, many researchor have focused on the
HBN relationship with liver diseases and its molecular-biological characteristics. Some vaccines have been developed to prevent infection but no effective therapy exists for treating hepatitis B infection.
In the past years, it was reported that some nucleoside compounds, which have been mainly developed as an anti-AIDS(Acquired Immune Deficiency Syndrome) agent, are effective HBN inhibitors J. Org. Chem., 1992, Vol. 57, 2217]. However, these nucleoside compounds as effective drugs against viral hepatitis B have proven to be undesirable due to high costs of drugs, adverse reactions and toxic effects.
Under such circumstances, there is urgent need for the development of hepatitis B drug having remarkable antiviral actions against HBN as a non- nucleoside compound. Recently, quinolones [European unexamined patent No. 563732 and No. 563734] and iridoids [Korean unexamined patent No. 94-1886] have been reported to have anti HBV activity but no significant development progress has been noticeable. To overcome the side effects and toxicities of the conventional drugs and develop some effective non-nucleoside compounds having remarkable antiviral actions against HBV, the inventor et al. have carried out intensive studies. As a result, the inventors have completed this invention wherein terephthalamide derivatives of non-nucleoside compounds with specific structure of the above formula 1 have been found to have potent inhibitory actions against the proliferation of HBN including human immunodeficiency virus (hereinafter referred to as "HIN") and other viruses.
For example, HBN is a virus different from HIN but during proliferation, they have common replication courses, i. e., a reverse transcription step and the resulting R A template of RΝA-DΝA hybrid is degraded. Since terephthalamide derivatives according to the present invention of the formula 1, have mechanism to inhibit such proliferation course, it may be developed as effective inhibitor against the proliferation of various viruses including HBN and HIN.
SUMMARY OF THE INVENTION
Therefore, an object of the present invention is to provide novel terephthalamide derivatives of the following formula 1, its pharmaceutically acceptable salts as antiviral agents having remarkable inhibitory activities against the proliferation of various viruses including HIV and HBV, and preparing method thereof.
Detailed Description of the Invention The present invention is related to novel terephthalamide derivatives of the following formula 1 and its pharmaceutically acceptable salts.
Figure imgf000006_0001
Wherein: Ri, R2 and R3 are the same as defined above, respectively.
The preferred terephthalamide derivatives of the formula 1 according to the present invention, are as follows:
In case where from the above Ri and R2, one is hydrogen atom and the other is an Cι~C3 alkoxy Cι~C alkyl group; di(C2~Cs alkoxy) Cι~C alkyl group; l,3-dioxolan-2-yl-methyl group; tetrahydrofuran-2-yl-methyl group; 2- (morpholin-4-yl) ethyl group; 3-(morpholin-4-yl)propyl group; 2-(piperidin-l- yl)ethyl group; di(Cι~C3 alkyl) amino Q-C3 alkyl group; 2-(acetylamino)ethyl group; 2-hydroxyethyl group; or substituted 2-hydroxyethyl group with one or two suitable substituents selected from phenyl group, benzyl group, Cι~C3 hydroxyalkyl group and Cι~Cs alkyl group,
In case where from the above Ri and R2, one is Cι~C3 alkyl group and the other is di(Cι~C3 alkoxy) C ~C3 alkyl group; l,3-dioxolan-2-yl-methyl group; tetrahydrofuran-2-yl-methyl group; 2-(morpholin-4-yl)ethyl group; 3- (morpholin-4-yl)propyl group; 2-(piperidin-l-yl)ethyl group; 2-hydroxyethyl group; di(Cι~C3 alkyl)amino Cι~C3 alkyl group; or 2-(acetylamino)ethyl group,
In case where the above Ri and R are simultaneously C1M3 alkyl group, hydroxyethyl group or 2-hydroxypropyl group, and
In case where the above Ri and R2 are combined with one or two hetero atoms selected from nitrogen, oxygen and sulfur to form heterocycles such as morpholine, thiomorpholine, pyrrolidine, piperidine or piperazine ring, in particularly in the case of piperazine ring it is selectively substituted with hydrogen atom, Cι~C5 alkyl group, C3~C6 cycloalkyl group, C2~Cs hydroxyalkyl group, C2~C dihydroxyalkyl group, C3--C5 (hydroxyalkoxy)alkyl group, Cι~C3 alkyl-substituted O- hydroxyalkyl group, (2R)-3-hydroxy-2- methylpropyl group or (2S)-3-hydroxy-2-methylpropyl group.
The more preferred terephthalamide derivatives of the formula 1 according to the present invention, are as follows:
In case where Ri is 2-hydroxyethyl group, while R2 is hydrogen atom, methyl, ethyl or isopropyl group,
In case where Ri and R2 are simultaneously 2-hydroxyethyl, 2- hydroxypropyl, ethyl or isopropyl group,
In case where Ri is hydrogen atom, while R is a substituted 2- hydroxyethyl group, showing (R)- or (S)-type of stereospecificity, in which a substituent in particular such as methyl, ethyl, isopropyl, phenyl, benzyl or hydroxymethyl group at 1- or 2-position, or substituted 2-hydroxyethyl group in which two substituents in particular such as methyl, ethyl or hydroxymethyl group at 1-position,
In case where Ri is hydrogen atom or 2-methoxyethyl group, while R is 2- methoxyethyl, 3-methoxypropyl, 3-ethoxypropyl or 3-isopropoxypropyl group, In case where R\ is hydrogen atom or methyl group, while R2 is 2,2- dimethoxyethyl, 2,2-diethoxyethyl, l,3-dioxolan-2-yl-methyl, tetrahydrofuran- 2-yl-methyl, 2-(morpholin-4-yl)ethyl, 3-(morpholin-4-yl)propyl or 2-(piperidin- l-yl)ethyl group, In case where Ri is hydrogen atom, methyl or ethyl group, while R is 2-
(dimethylamino)ethyl, 2-(diethylamino)ethyl, 3-(dimethylamino)propyl, 3- (diethylamino)propyl or 2-(acetylamino)ethyl group,
In case where Ri and R2 are forming heterocycles such as morpholine, thiomorpholine, pyrrolidine, piperidine or piperazine ring, together with nitrogen atom,
In case where Ri and R2 are forming a piperazine ring, while the nitrogen atom at 4-position is selectively substituted with methyl, ethyl, isopropyl, cyclopropyl, cyclopentyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3- dihydroxypropyl, 2,2-dimethyl-3-hydroxypropyl, (2R)-3-hydroxy-2- methylpropyl, (2S)-3-hydroxy-2-methylpropyl or 2-(2-hydroxyethoxy)ethyl group, and
In particular preferred terephthalamide derivatives of the formula 1, both Ri and R2 are the same as defined above, while R3 is an isopropyl group.
According to the present invention, the typical examples of terephthalamide derivatives of the above formula 1, are as follows: l-[N-(2-Hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 1), 1 - [N-(3-Hy droxy propy l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 2),
1 - [N-(4-Hy droxy buty l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 3),
1 - [N-(5-Hy droxy penty l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 4),
1 - [N-(2-Hy droxy ethy l)-N-methy lcarbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 5), l-[N-Ethyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 6), l-[N-(2-Hydroxyethyl)-N-propylcarbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 7), l-[N-(2-Hydroxyethyl)-N-(l-methylethyl)carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 8), l-[N-Butyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 9), l-[N-Benzyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 10), l-[N-(2-Hydroxyethyl)-N-phenylcarbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 11),
1 - [N, N-Bis (2-hy droxy ethy l)carbamoy 1] -4- [1 - [3-(isopr opy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 12), l-[N,N-Diethylcarbamoyl]-4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4- yl-carbonyl]benzene (Compound No. 13), l-[N,N-Bis(l-methylethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl] piperazin-4-y 1-carbony 1] benzene (Compound No. 14),
4- [1 - [3-(Isopropy lamino)-2-py r idy 1] piperazin-4-y 1-carbony 1] -1 -(N-methy 1- N-propylcarbamoyl)benzene (Compound No. 15),
1 - [N, N-Bis (2-hy droxy propy l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 16), l-[N-[2-(2-Hydroxyethoxy)ethyl]carbamoyι]- -[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 17), l-[N-Ethyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(ethylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 18),
1 - [4- [1 - [3-(Isopropy lamino)-2-py r idy 1] piperazin-4-y 1- carbonyl]benzoyl]piperazine (Compound No. 19),
1 - [4- [1 - [3-(Isopropy lamino)-2-py r idy 1] piperazin-4-y 1-carbony l]benzoy 1] -4- methylpiperazine (Compound No. 20),
4-Ethy 1-1 -[4- [1 - [3-(isopropy lamino)-2-py r idy 1] piperazin-4-y 1- carbonyl]benzoyl]piperazine (Compound No. 21),
4-Cy clopenty 1-1 - [4- [1 - [3-(isopropy lamino)-2-py ridy 1] piper azin-4-yl- carbonyl]benzoyl]piperazine (Compound No. 22),
1 - [4- [1 - [3-(Isopropy lamino)-2-py r idy 1] piperai' in-4-y 1-carbony 1] benzoy 1] -4- propylpiperazine (Compound No. 23),
1 - [4- [1 -[3-(Isopropylamino)-2-pyridyl] piperazin-4-y 1-carbony l]benzoyl] -4- (1-methylethyl) piperazine (Compound No. 24),
4-Cy clopropy 1-1 - [4- [1 - [3-(isopropy lamino)-2-py ridy 1] piperazin-4-y 1- carbonyl]benzoyl]piperazine (Compound No. 25),
4-(2-Hydroxyethyl)-l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoyl] piperazine (Compound No. 26), 4-(3-Hydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl] benzoy 1] piperazine (Compound No. 27),
4-[(2R)-3-Hydroxy-2-methylproρyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine (Compound No. 28),
4-[(2S)-3-Hydroxy-2-methylpropyl]-l-[4-[l-[3-(isopropylamino)-2- pyr idyl] piper azin-4-y 1-carbony 1] benzoy 1] piperazine (Compound No. 29),
4-(2,2-Dimethyl-3-hydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine (Compound No. 30),
4-(2,3-Dihydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin- 4-yl-carbonyl]benzoyl]piperazine (Compound No. 31), 4-[2-(2-Hydroxyethoxy)ethyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine (Compound No. 32), l-[4-[l-[3-(Ethylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoyl]-4-(2- hydroxyethyl)piperazine (Compound No. 33),
1 - [N-(l ,1 -Dimethy 1-2-hy droxy ethy l)carbamoy 1] -4- [1 - [3-(isopropy lamino) - 2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 34), l-[N-[(lS)-2-Hydroxy-l-methylethyl]carbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 35),
1 - [N- [(1 R)-2-Hy droxy-1-methylethy 1] carbamoy 1] -4- [1 - [3-(isopr opy lamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 36),
1 - [N-(2-Hy droxy-1 -methy lethy l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 37), l-[N-[(lS)-2-Hydroxy-l-(l-methylethyl)ethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 38), l-[N-[(lR)-2-Hydroxy-l-(l-methylethyl)ethy carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 39), l-[N-[2-Hydroxy-l-(l-methylethyl)ethyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 40),
1 - [N- [(1 S)-l -Ethy 1-2-hy droxy ethyl] carbamoy 1] -4- [1 - [3-(isopr opy lamino)-2- pyridyl] piperazin-4-y 1-carbony 1] benzene (Compound No. 41), l-[N-[(lR)-l-Ethyl-2-hydroxyethyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 42), l-[N-(l-Ethyl-2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl] iperazin-4-y 1-carbony 1] benzene (Compound No. 43), l-[N-[(lS)-2-Hydroxy-l-(2-methylpropyl)ethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 44), l-[N-[(lR)-2-Hydroxy-l-(2-methylpropyl)ethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 45), l-[N-[(lS)-2-Hydroxy-l-(l-methylpropyl)ethyl]carbamoyl]-4-[l-[3-
(isopropy lamino)-2-py ridy 1] piperazin-4-y 1-carbony 1] benzene (Compound No . 46), l-[N-[(lS)-l-(Cyclohexylmethyl)-2-hydroxye yl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 47), l-[N-[(lS)-2-Hydroxy-l-phenylethyl]carbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 48), l-[N-[(lR)-2-Hydroxy-l-phenylethyl]carbamoyl]-4-[l-[3-(isopropylamino)-
2-pyridyl] piperazin-4-y 1-carbony l]benzene (Compound No. 49), l-[N-[(lS)-l-Benzyl-2-hydroxyethyl]carbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl] piperazin-4-y 1-carbony 1] benzene (Compound No. 50), l-[N-[(lR)-l-Benzyl-2-hydroxyethyl]carbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 51), l-[N-[Bis(hydroxymethyl)methyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 52),
1 - [N- [1 ,1 -Bis(hy droxy methy l)ethy 1] carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 53), l-[N-[l,l-Bis(hydroxymethyl)propyl]carbamoyl]-4-[l-[3-(isopropylamino)-
2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 54), l-[N-[Tris(hydroxymethyl)methyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 55),
1 - [N- [(2S)-2-Hy droxy propyl] carbamoy 1] -4- [1 -[3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 56),
1 - [N- [(2R)-2-Hy droxy propyl] carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl] piperazin-4-y 1-carbony l]benzene (Compound No. 57), l-[N-(2-Hydroxypropyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 58), l-[N-(2-Hydroxy-2-phenylethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 59), l-[N-(2,3-Dihydroxypropyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 60), 4- [1 - [3-(Isopropy lamino)-2-py ridy 1] piperazin-4-y 1-carbony 1] -1 - [N-(2- methoxyethyl)carbamoyl]benzene (Compound No. 61),
1- [N, N-Bis (2-methoxy ethy l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 62), 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N-(2- methoxy-l-methylethyl)carbamoyl]benzene (Compound No. 63),
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N-(3- methoxypropyl)carbamoyl]benzene (Compound No. 64), l-[N-(3-Ethoxypropyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 65), l-[N-(3-Isopropoxypropyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 66),
4- [1 - [3-(Isopropy lamino)-2-py r idy 1] piper azin-4-y 1-carbony 1] -1 - [N- [3- (vinyloxy)propyl]carbamoyl]benzene (Compound No. 67), l-[N-(2,2-Dimethoxyethyl)-N-methylcarbamoyl]-4-[l-[3-(isopropylamino)-
2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 68),
1 - [N-(2,2-Dimethoxy ethy l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl] piperazin-4-y 1-car bony 1] benzene (Compound No. 69), l-[N-(2,2-Diethoxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 70), l-[N-[(l,3-Dioxolan-2-yl)methyl]-N-methylcarbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 71),
4- [1 - [3-(Isopropy lamino)-2-py ridy 1] piperazin-4-y 1-carbony 1] -1 - [N- [(tetrahydrofuran-2-yl)methyl]carbamoyl]benzene (Compound No. 72),
4- [1 - [3-(Isopr opy lamino)-2-py ridy 1] piper azin-4-y 1-carbony 1] -1- [N- [ [(2R)- tetrahydrofuran-2-yl] methyl] carbamoy 1] benzene (Compound No. 73),
4- [1 - [3-(Isopropy lamino)-2-py ridy 1] piperazin-4-y 1-carbony 1] -1 - [N- [[(2S)- tetrahydrofuran-2-yl]methyl]carbamoyl]benzer-e (Compound No. 74), l-[N-[(Furan-2-yl)methyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 75),
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-(morpholin- 4-yl-carbonyl)benzene (Compound No. 76),
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l- (thiomorpholin-4-yl-carbonyl)benzene (Compound No. 77),
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-(thiazolidin- 3-yl-carbonyl)benzene (Compound No. 78), 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N-[2-
(morpholin-4-yl)ethyl]carbamoyl]benzene (Compound No. 79),
4- [1 - [3-(Isopr opy lamino)-2-py ridy 1] piper azin-4-y 1-carbony 1] -1 - [N- [3- (morpholin-4-yl)propyl]carbamoyl]benzene (Compound No. 80),
4- [1- [3-(Isopropy lamino)-2-py ridy 1] piper azin-4-y 1-carbony 1] -1 - [N- [2- (piperidin-l-yl)ethyl]carbamoyl]benzene (Compound No. 81),
4- [1 - [3-(Isopr opy lamino)-2-py ridy 1] piper azin-4-y 1-carbony 1] -1- [N- [2- (pyrrolidin-l-yl)ethyl]carbamoyl]benzene (Compound No. 82),
1 - [N- [2-(Dimethy lamino)ethy 1] carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl] piper azin-4-y 1-carbony 1] benzene (Compound No. 83), l-[N-[2-(Dimethylamino)ethyl]-N-methylcarbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 84), l-[N-[2-(Dimethylamino)ethyl]-N-ethylcarbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 85), l-[N-[2-(Diethylamino)ethyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 86), l-[N-[2-(Diethylamino)ethyl]-N-methylcarbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 87), l-[N-[2-(Diethylamino)ethyl]-N-ethylcarbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 88), l-[N-[3-(Dimethylamino)propyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- py ridy l]piperazin-4-y 1-carbony l]benzene (Compound No. 89),
1 - [N- [3-(Dimethy lamino)propy 1] -N-methy lcarbamoy 1] -4- [1 - [3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 90), l-[N-[3-(Diethylamino)propyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 91), l-[N-[2-(Acetylamino)ethyl]carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene (Compound No. 92),
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-(piperidin- l-yl-carbonyl)benzene (Compound No. 93),
4- [1 - [3-(Isopropy lamino)-2 -py ridy 1] piper azin-4-y 1-carbony 1] -1 -(py rr olidin- l-yl-carbonyl)benzene (Compound No. 94).
Further, terephthalamide derivatives of the above formula 1 according to the present invention may form its pharmaceutically acceptable acid-addition salts with acid in accordance with some ordinary methods in the art to which the present invention pertains. For example, the acid-addition salts may include inorganic acids(e. g., hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid) or organic acids(e. g., formic acid, acetic acid, propionic acid, oxalic acid, citric acid, maleic acid or methanesulfonic acid). Since terephthalamide derivatives of the above formula 1 according to the present invention has potent effects against the proliferation of HBV and HIV, it may be used as a clinically useful anti-hepatitis B agent and anti-AIDS agent.
Therefore, the present invention includes pharmaceutical compositions containing the terephthalamide derivatives of the above formula 1, and its pharmaceutically acceptable salts as active ingredients.
When pharmaceutical compositions of the present invention is intended for clinical application, it may be formulated into several dosage forms containing some exipients commonly used in pharmaceutical field; for example, oral preparations(e. g., tablets, capsules, troches, solutions or suspensions); injectables(e. g., injectable solution or suspension, or injectable dry powder which can be immediately used by adding water for injection prior to injection); topical preparations(e. g., ointments, creams or solutions). The vehicles used for pharmaceutical compositions of the present invention are common types available m the pharmaceutical field, which include; binders, lubricants, disintegrants, excipients, solubilizers, diluents, stabilizers, suspending agent, pigments, flavors, etc. for oral preparations; preservatives, solubilizers, stabilizers, etc. for injectable preparations; bases, diluents, lubricants preservatives, etc. for topical preparations. The pharmaceutical preparations may be administered orally or parenterally(e. g., intravenously, subcutaneously, intraperitoneally or topically). Some drugs may be formulated as an enteric coated tablet when they are unstable in gastric condition. Further the clinical dose of terephthalamide derivatives of the above formula 1 in patients, may be appropriately determined according to therapeutic efficacy and bioavailability of active ingredients in the body, their metabolism and excretion rate, and age, sex, stage of target diseases of the patient but generally, the daily dose of adult should be given at 10 ~ 500 mg, preferably at 50 ~ 300 mg. Therefore, when pharmaceutical compositions of the present invention is prepared as an unit dosage form, the formulation of each unit should be made available so as to contain 10 ~ 500 mg of terephthalamide derivatives of the above formula 1, preferably 50 ~ 300 mg, in consideration of the above mentioned effective dose. These preparations may be administered at certain intervals of several times(preferably one to 6 times) in accordance with medical doctor or pharmacist's direction.
The present invention also includes a process of preparing terephthalamide derivatives of the present invention of the above formula 1. And the terephthalamide derivatives may be prepared by the following reaction schemes 1, 2 and 3.
The following reaction scheme 1 is a schematic diagram showing a process of preparing terephthalamide derivatives of the above formula 1 as a desired product by reacting a compound of the formula 2 and some amine compounds. [Reaction scheme 1]
Figure imgf000017_0001
1
Wherein: Ri, R2 and R3 are the same as defined in the above, respectively.
According to the reaction scheme 1, terephthalic acid derivatives of the formula 2, is reacted with some acid chloride(e. g., pivaloyl chloride) to form an acid anhydride with good reactivity; then, the intermediate is further reacted with amine compounds of the formula 3, to obtain terephthalamide derivatives of the above formula 1 as a desired product. Such reaction is completed at 0 ~ 30 °C within 6 hours in the presence of the general tertiary organic bases such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, N- methylpiperidine, 4-dimethylaminopyridine, N,N-dimethylaniline, 2,6-lutidine or pyridine. It is preferred to use a single solvent or co-solvent selected from chloroform, methylene chloride, acetonitrile, tetrahydrofuran, dioxane, dioxolane, N,N-dimethylformamide, N,N-dimethylacetamide and N- methylpyrrolidone.
Another direct process of preparing terephthalamide derivatives of the above formula 1 as a desired product via reaction between a compound of the following formula 4, a precursor of a compound of formula 2 used in the above reaction scheme 1 and some amine compounds and its preparing process is illustrated in the following reaction scheme 2. Namely, this method has an advantage of shortening one processing step of starting material. [Reaction scheme 2]
Figure imgf000018_0001
1 Wherein: Ri, R2 and R3 are the same as defined in the above, respectively.
According to the reaction scheme 2, the reaction is carried out under direct nucleophilic substitution between amine compounds of the formula 3 and methyl ester group of terephthalic acid ester derivatives of the formula 4.
Since the reactivity of the reaction scheme 2 is relatively lower than that of the reaction scheme 1 using acid anhydride with good reactivity, more vigorous reaction conditions should be required. The nucleophilic substitution reaction is completed at 40 ~ 90 °C within 20 hours using some alcoholic solvents(e. g., methanol, ethanol, propanol, isopropanol or butanol) or polar organic solvents(e. g., acetonitrile, N,N- dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone).
Further, the amine compounds of the formula 3 used in the reaction scheme 1 and 2, are reagents intended for introducing the substituents Ri and
R2 into terephthalamide derivatives of the formula 1 as a desired product.
Some appropriate amine compounds, selected by required substituents, may be easily used by a person having ordinary skill in the art to which the this invention pertains. Further, in case that Ri and R2 combine with nitrogen atom to form a piperazine ring, a desired product can be prepared by the following reaction scheme 3 in addition to the reaction scheme 1 and 2.
[Reaction scheme 3]
Figure imgf000020_0001
Wherein:
R3 is the same as defined in the formula 1;
R represents hydrogen atom, Ci-Cs alkyl group, C3~Cs cycloalkyl group, Ci-Cs hydroxyalkyl group, C2~Cs dihydroxyalkyl group, C2~Cs (hy droxy alkoxy )alkyl group, Ci~C3 alkyl-substituted Cι~C hydroxyalkyl group, (2R)-3-hydroxy-2-methylpropyl or (2S)-3-hydroxy-2-methylpropyl group;
X represents halogen atom.
Reaction is carried out in such a manner that terephthalic acid derivatives of the formula 2 as a starting material of the reaction scheme 1, is reacted with some acid chloride(e. g., pivaloyl chloride) to form an acid anhydride with good reactivity; then, the intermediate is further reacted with piperazine of the formula 5, to obtain terephthalamide derivatives of the above mentioned formula la as a desired product. Such react. on is completed at 0 ~ 30 °C within 6 hours in the presence of excess of piperazine of the formula 5, or the general tertiary organic bases such as triethylamine, pyridine, 4- dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N- methylmorpholine or 2,6-lutidine. It is preferred to use the solvent selected from methylene chloride, chloroform or acetonitrile. In addition, in case that other different substituent is intended for introduction at 4-position of the piperazine ring, the substitution reaction is carried out between terephthalamide derivatives of the formula la and halogen compounds of the formula 6. It is preferred to carry out the substitution reaction in polar solvents such as methanol, ethanol, isopropanol, butanol, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide or N- methylpyrrolidone. The reaction is quantitatively carried out at 50 ~ 110 °C within 30 hours in the presence of tertiary organic bases such as triethylamine, N-methy lmorpholine, N-methylpiperidine or 2,6-lutidine.
Further, in the process of preparing compounds of the formula 1 based on the reaction scheme 1 and 2, each compound used as a starting material of the formula 2 or 4, respectively, can be prepared by the following reaction scheme 4 prior to use. [Reaction scheme 4]
Figure imgf000022_0001
Figure imgf000022_0002
10
Figure imgf000022_0003
Wherein: R3 is the same as defined in the formula 1.
The raw materials used for the reaction scheme 4(e. g., 2-chloro-3- nitropyridine of the formula 7, piperazine of the formula 5, and mono-methyl terephthalate of the formula 9 have been currently on the market and may be easily purchased. Further, pyridylpiperazine derivative of the formula 8 is a known compound listed in literatures and may be easily prepared by the known process [/. Med. Chem., 1994, Vol. 37, 999 ~ 1014] prior to use.
First, mono-methyl terephthalate of the formula 9 is reacted with some acid chloride(e. g., pivaloyl chloride) to form an acid anhydride with good reactivity; then, the intermediate is further reacted with pyridylpiperazine derivative of the formula 8, to obtain terephthalic acid ester derivative including nitropyridyl group of the above mentioned formula 10. Such reaction is completed at 0 ~ 30 °C within 5 hours in the presence of tertiary organic bases. The main solvents used for this reaction include some non- polar solvents such as methylene chloride, chloroform, etc..
The compound of the formula 10 is reduced by catalytic hydrogenation to give the compound including aminopyridyl group of the formula 11. Such reduction may be well carried out under high-pressure condition using hydrogen gas in the presence of small amounts of activated metal catalysts such as Raney-nickel or palladium on activated carbon, being widely used in the reductive reaction. Various solvents such as methanol, ethanol, methylene chloride, chloroform or ethyl acetate may be used for this reaction. Further, the compound including aminopyridyl group of the formula 11 are under reductive alkylation with acetone or acetaldehyde in the presence of a selective reducing agent such as sodium cyanoborohydride under acidic conditions to form terephthalic acid ester derivatives including isopropylamino or ethylamino group, expressed by the formula 4. Such reaction may be well carried out in the presence of some organic acids such as acetic acid and in general, alcoholic solvents such as methanol or ethanol are used.
When terephthalic acid ester derivatives, so formed and expressed by the formula 4 are hydrolyzed, terephthalic acid derivatives of the formula 2 is obtained and the solvents used for this reaction include a co-solvent where water is added to lower alcohols such as methanol, ethanol or isopropanol. The hydrolysis is completed at below 40 °C within 3 hours.
The present invention is explained in more detail by the following preparations examples and examples but is not limited by these examples.
Preparation example 1: Preparation of l-(3-nitro-2-pyridyl)piperazine
Anhydrous piperazine (60 g) was dissolved in methylene chloride (400 ml) and then, 2-chloro-3-nitropyridine (40 g) was added slowly at 10 ~ 20 °C and the mixture was stirred at 20 °C for 2 hours. After completion of the reaction, the reaction mixture was washed with water (300 ml) three times and the separated organic layers were concentrated under reduced pressure. The precipitate was washed with water and small amount of ethanol and dried in vacuo to give 46 g (yield: 87.5%) of the desired compound, m.p. : 79 ~ 82°C
Η-NMR(CDC13), ppm : δ 1.93(s, 1H), 2.95(m, 4H), 3.41 (m, 4H), 6.71 (m, 1H),
8.10(m,lH), 8.30(m, 1H)
Preparation example 2: Preparation of 4-[l-(3-nitro-2-pyridyl)piperazin-4-yl- carbonyl]benzoic acid methyl ester
To the solution of mono-methyl terephthalate (20 g) in methylene chloride (380 ml), triethylamine (18.2 ml) was added and cooled. Then, pivaloyl chloride (15 ml) was added to the solution at 0 ~ 5°C and stirred at 5°C for 2 hours. l-(3-Nitro-2-pyridyl)piperazine (21.3 g) and triethylamine (18.6 ml) were added to the reaction mixture in order and the mixture was stirred at 5 ~ 10 °C for 2 hours. The reaction mixture was washed with aqueous sodium bicarbonate and water twice and the separated organic layers were concentrated under reduced pressure. The precipitated yellow solid was treated with ether (250 ml) for 1 hour, filtered and dried to give 17.2 g (yield: 91%) of the desired compound as bright yellow crystal, m.p. : 149 ~ 152°C Η-NMR(CDC13), ppm : δ 3.38(m, 2H), 3.53(m, 4H), 3.92(m, 5H), 6.81(m, 1H), 7.48(m, 2H), 8.08( , 2H), 8.17(m, 1H), 8.35(m, 1H)
Preparation example 3: Preparation of 4-[l-(3-amino-2-pyridyl)piperazin-4-yl- carbonyl]benzoic acid methyl ester 4-[l-(3-Nitro-2-pyridyl)piperazin-4-yl-carbonyl]benzoic acid methyl ester
(5 g) was dissolved in a co-solvent of methanol (80 ml) and methylene chloride (60 ml) in a pressurized reactor. With the addition of about 1 g of Raney- nickel (50% slurry in water), the reaction mixture was filled with hydrogen gas and stirred at 50 ~ 60 psi for 4 hours. After completion of the reaction, reaction mixture was filtered through celite and filtrate was concentrated under reduced pressure. The concentrated residue was treated with hexane and ether for crystallization, filtered, washed and dried to give 4.05 g (yield: 88%) of the desired compound, m.p. : 144°C Η-NMR(CDC13), ppm : δ 3.15(m, 4H), 3.47(m, 2H), 3.82~3.91(m, 7H), 6.87(m,
1H), 6.97(m, 1H), 7.48(m, 2H), 7.78(m, 1H), 8.07(m, 2H)
Preparation example 4: Preparation of 4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoic acid methyl ester
4-[l-(3-Amino-2-pyridyl)piperazin-4-yl-carbonyl]benzoic acid methyl ester (4 g) was dissolved in methanol (90 ml) and then, acetone (2 ml), acetic acid (5 ml) and sodium cyanoborohydride (2.4 g) were added at 10 °C in order. The reaction mixture was stirred at 10°C for 4 hours and heated to 20 ~ 25 °C and stirred for 1 hour. The solution was neutralized (pH = ~8) by addition of aqueous 3N-sodium hydroxide, and excess of water was added gradually for precipitation. The mixture was stirred for 1 hour, filtered, washed with water, methanol and ether in order and dried to give 3.5 g (yield: 78%) of the desired compound as white crystal, m.p. : 116 ~ 118 TJ
Η-NMR(CDCl3), ppm : δ 1.24(d, 6H), 3.12(m, 4H), 3.53(m, 3H), 3.91(m, 5H),
4.14(m, 1H), 7.02(m, 1H), 7.08(m,lH), 7.49(m, 1H), 7.76(m, 1H), 8.08(m, 2H)
Preparation example 5: Preparation of 4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoic acid
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl] benzoic acid methyl ester (3 g) was dissolved in methanol (47 ml) and then, aqueous 1N- sodium hydroxide (16 ml) was added slowly. The solution was stirred at
20 ~ 25 °C for 3 hours. 2N-HC1 was added slowly to the mixture for neutralization (pH = ~5) and then, the crystalline powder was precipitated. The crystalline powder was filtered, washed with water and methanol and dried to give 2.7 g (yield: 93%) of the desired compound. m.p. : 215 ~ 217°C
Η-NMR(CDC1 ), ppm : δ 1.24(d, 6H), 3.17(m, 4H), 3.56(m, 3H), 3.93(m, 2H),
6.91 (m, 1H), 7.03(m, 1H), 7.56(m,2H), 7.87(m, 1H), 8.16(m, 2H)
Preparation example 6: Preparation of 4-[l-[3-(ethylamino)-2- py ridy 1] piper azin-4-y 1-carbony ljbenzoic acid methyl ester
4-[l-(3-Amino-2-pyridyl)piperazin-4-yl-carbonyl]benzoic acid methyl ester (4 g) was dissolved in methanol (80 ml) and then, acetaldehyde (1.7 ml) and acetic acid (4 ml) were added at 0°C . The solution was stirred at 0°C for
30 minutes. Then, with the addition of sodium cyanoborohydride (2.2 g), the solution was stirred at 0 ~ 5 °C for 2 hours. Excess of water was added gradually, and the solution was neutralized (pH - ~8) by addition of aqueous 3N-sodium hydroxide. The mixture was stirred for 1 hour and filtered, and the crude solid was recrystallized using methanol and ether to give 3.51 g (yield: 81%) of the desired compound, m.p. : 96 ~ 97 °C Η-NMR(CDC13), ppm : δ 1.28(t, 3H), 3.12(m, 6H), 3.52(m, 2H), 3.92(m, 5H),
4.18(m, 1H), 6.85(m, 1H), 6.96(m,lH), 7.48(m, 2H), 7.70(m, 1H), 8.06(m, 2H)
Preparation example 7: Preparation of 4-[l-[3-(ethylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoic acid
By the same procedure as described in the preparation example 5, 4-[l-[3- (ethy lamino)-2-py ridy l]piperazin-4-yl-car bony l]benzoic acid methyl ester was hydrolyzed to give a desired product. Yield: 91 % m.p. : 208 ~ 209 °C
Η-NMR(CDC13), ppm : δ 1.30(t, 3H), 3.16(m, 6H), 3.48(m, 2H), 3.94(m, 2H),
6.95(m, 1H), 7.05(m,lH), 7.56(m, 2H), 7.91(m, 1H), 8.15(m, 2H)
Example 1: l-[N-(2-Hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
4- [1 - [3-(Isopr opy lamino)-2-py ridy 1] pipera.zin-4-y 1-carbony 1] benzoic acid (1.5 g) was dissolved in methylene chloride (50 ml) and then, triethylamine (0.7 ml) was added and cooled. Pivaloyl chloride(0.58 ml) was added slowly to the solution at 0 ~ 5 °C and the mixture was stirred at 5 °C for 2 hours. And then, triethylamine (0.7 ml) and 2-aminoethanol(0.27 g) were added in order, the solution was stirred at 0 ~ 5 °C for 2 hours and heated slowly to 20 ~ 25 °C and stirred for 30 minutes. The reaction mixture was washed with water twice and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and further recrystallized using isopropanol and ether. The recrystallized product was filtered and dried to give 1.34 g (yield: 80%) of the desired compound as a white powder. m.p. : 182 ~ 184 °C
Η-NMR(CDC13), ppm : δ 1.20(d, 6H), 3.07(m, 4H), 3.51 (m, 3H), 3.58(m, 2H),
3.76(m, 2H), 3.85(m, 2H), 6.83(m, 1H), 6.94(m, 1H), 7.07(m, 1H), 7.36(m, 2H), 7.63(m, 1H), 7.77(m, 2H)
Example 2: l-[N-(3-Hydroxypropyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 1, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using 3-amino-l-propanol. Then, the product was recrystallized using ethyl acetate and ether to give the desired compound. Yield: 76 % m.p. : 110 ~ lil t
Η-NMR(CDC13), ppm : δ 1.23(d, 6H), 1.80(m, 2H), 3.11(m, 4H), 3.50(m, 3H), 3.59(m, 2H), 3.72(m, 2H), 3.90(m, 2H), 4.15(m, 1H),
6.86(m, 1H), 6.97(m, 1H), 7.12(m, 1H), 7.44(m, 2H), 7.67(m, 1H), 7.78(m, 2H)
Example 3 : 1 - [N-(4-Hy droxy buty l)carbamoy 1] -4- [1 - [3-(isopropy lamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 1, synthesis was carried out starting with 4-[l-[3-(isopropyϊdmino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using 4-amino-l-butanol. Then, the product was recrystallized using ethyl acetate and isopropyl ether to give the desired compound. Yield: 84 %
Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 1.51(m, 2H), 1.62(m, 2H), 3.10(m, 4H), 3.51 (m, 5H), 3.73(m, 2H), 3.92(m, 2H), 4.13(m, 1H),
6.84(m, 1H), 6.95(m, 1H), 7.11 (m, 1H), 7.45(m, 2H),
7.64(m, 1H), 7.79(m, 2H)
Example 4: l-[N-(5-Hydroxypentyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained b}- the same synthetic method as described in the Example 1. Yield : 74 %
Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 1.42~1.51(m, 6H), 3.10(m, 4H), 3.50(m, 5H), 3.71(m, 2H), 3.91(m, 2H), 4.13(m, 1H), 6.82(m,
1H), 6.94(m, 1H), 7.10(m, 1H), 7.44(m, 2H), 7.64(m, 1H), 7.77(m, 2H)
Example 5: l-[N-(2-Hydroxyethyl)-N-methylcarbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 1. Yield: 77 % m.p. : 131 ~ 132°C Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 3.02(s, 3H), 3.11(m, 4H), 3.53(m, 3H),
3.72(m, 2H), 3.89(m, 3H), 4.15(m, 1H), 6.84(m, 1H), 6.95(m, 1H), 7.48(m, 4H), 7.68(m, 1H) Example 6: l-[N-Ethyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 1, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- 5 carbonyl]benzoic acid and using 2-(ethylamino)ethanol. Then, the product was recrystallized using ethyl acetate and petroleum ether, filtered and dried to give the desired compound as white crystal. Yield: 86 % m.p. : 115°C l o Η-NMR(CDC13), ppm : δ l.ll(t, 3H), 1.20(d, 6H), 3.06(m, 4H), 3.31 (m, 2H),
3.52(m, 4H), 3.68(m, 2H), 3.87(m, 3H), 4.14(m, 1H), 6.83(m, 1H), 6.93(m, 1H), 7.45(m, 4H), 7.66(m, 1H)
Example 7: l-[N-(2-Hydroxyethyl)-N-propylcarbamoyl]-4-[l-[3-
15 (isopropylamino)-2-pyridyl]pip razin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 6. Yield: 82 % m.p. : 79 ~ 82°C 20 Η-NMR(CDC13), ppm : δ 0.77(t, 3H), 1.23(d, 6H), 1.56(m, 2H), 3.14~3.24(m,
6H), 3.53(m, 4H), 3.70(m, 2H), 3.89(m, 3H), 4.15(m, 1H), 6.91 (m, 1H), 6.98(m, 1H), 7.46(m, 4H), 7.70(m, 1H)
Example 8: l-[N-(2-Hydroxyethyl)-N-(l-methylethyl)carbamoyl]-4-[l-[3- 25 (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 6. Yield: 85 % Η-NMR(CDC13), ppm : δ 1.21(m, 12H), 3.06(m, 4H), 3.51(m, 6H), 3.80(m, 2H),
3.91(m, 2H), 4.13(m, 1H), 6.90(m, 1H), 6.97(m, 1H), 7.47(m, 4H), 7.70(m, 1H)
Example 9: l-[N-Butyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 6. Yield: 75 % Η-NMR(CDC13), ppm : δ 0.79(t, 3H), 1.21(d, 6H), 1.48(m, 4H), 3.20(m, 6H),
3.52(m, 4H), 3.70(m, 2H), 3.88(m, 3H), 4.13(m, 1H), 6.90(m, 1H), 6.97(m, 1H), 7.45(m, 4H), 7.70(m, 1H)
Example 10: l-[N-Benzyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 1, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using 2-(benzylamino)ethanol. Then, the product was recrystallized using isopropanol and isopropyl ether, filtered and dried to give the desired compound. Yield: 81 % m.p. : 99 ~ 101 TJ
Η-NMR(CDCl3), ppm : δ 1.22(d, 6H), 3.11(m, 4H), 3.53(m, 3H), 3.69(m, 2H),
3.81(m, 2H), 3.89(m, 2H), 4.58(s, 2H), 6.87(m, 1H), 6.96(m, 1H), 7.16(m, 2H), 7.28(m, 1H), 7.35(m, 2H),
7.44~7.52(m, 4H), 7.68(m, 1H)
Example 11: l-[N-(2-Hydroxyethyl)-N-phenylcarbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 10. Yield: 76 % m.p. : 71 ~ 72°C
Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 3.08(m, 4H), 3.42(m, 2H), 3.53(m, IH),
3.84(m, 2H), 4.21(m, 2H), 6.88(m, IH), 6.96(m, IH), 7.07(m, 2H), 7.16(m, IH), 7.25(m, 4H), 7.36(m, 2H), 7.68(m, IH)
Example 12: l-[N,N-Bis(2-hydroxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- py ridy 1] piperazin-4-y 1-carbony 1] benzene
The desired compound was obtained by the same synthetic method as described in the Example 10. Yield : 83 % m.p. : 161 ~ 162 °C
Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 3.13(m, 4H), 3.41(m, 2H), 3.56(m, 3H),
3.70(m, 5H), 3.96(m, 3H), 6.89(m, IH), 6.97(m, IH), 7.49(m, 2H), 7.55(m, 2H), 7.68(m, IH)
Example 13: l-[N,N-Diethylcarbamoyl]-4-[l-[3-(isopropylamino)-2- py ridy 1] piperazin-4-y 1-carbony 1] benzene
The desired compound was obtained by the same synthetic method as described in the Example 1. Yield : 80 % m.p. : 78 ~ 80 °C
Η-NMR(CDC13), ppm : δ 1.08(t, 3H), 1.22(m, 9H), 3.11(m, 4H), 3.21(m, 2H),
3.53(m, 5H), 3.91(m, 2H), 4.15(m, IH), 6.84(m, IH), 6.95(m, IH), 7.39(m, 2H), 7.44(m, 2H), 7.68(m, IH)
Example 14 : l-[N,N-Bis(l-methylethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- py r idy 1] piper azin-4-y 1-carbony 1] benzene The desired compound was obtained by the same synthetic method as described in the Example 1.
Yield : 72 % m.p. : 152 ~ 153 °C
Η-NMR(CDC13), ppm : δ 1.16(m, 6H), 1.24(d, 6H), 1.50(m, 6H), 3.14(m, 4H), 3.53(m, 3H), 3.87(m, 4H), 6.90(m, IH), 6.97(m, IH),
7.36(m, 2H), 7.48(m, 2H), 7.69(m, IH)
Example 15: l-[N,N-Bis(2-hydroxypropyl)carbamoyl]-4-[l-[3-(isopropylamino)-
2-pyridyl]piperazin-4-yl-carbonyl]benzene The desired compound was obtained by the same synthetic method as described in the Example 10.
Yield : 77 % m.p. : 73 ~ 75 °C
Η-NMR(CDC13), ppm : δ l.ll(d, 3H), 1.21(d, 9H), 3.05(m, 4H), 3.51(m, 5H), 3.80(m, 4H), 4.10(m, 2H), 6.82(m, IH), 6.93(m, IH),
7.46(m, 4H), 7.66(m, IH)
Example 16: l-[N-[2-(2-Hydroxyethoxy)ethyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene The desired compound was obtained by the same synthetic method as described in the Example 1. Yield: 82 % m.p. : 116 °C Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 3.10(m, 4H), 3.51(m, 3H), 3.60(m, 2H),
3.68(m, 4H), 3.76(m, 2H), 3.90(m, 2H), 4.16(m, IH), 6.84(m, IH), 6.95(m, 2H), 7.44(m, 2H), 7.67(m, IH), 7.80(m, 2H)
Example 17: l-[N-Ethyl-N-(2-hydroxyethyl)carbamoyl]-4-[l-[3-(ethylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 1, synthesis was carried out starting with 4-[l-[3-(ethylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using 2-(ethylamino)ethanol. Then, the product was recrystallized using ethyl acetate and hexane to give the desired compound.
Yield: 72 % m.p. : 106 ~ 108°C
Η-NMR(CDC13), ppm : δ 1.12(t, 3H), 1.26(t, 3H), 3.12(m, 6H), 3.30(m, 2H), 3.53(m, 3H), 3.69(m, 2H), 3.89(m, 3H), 4.19(m, IH),
6.84(m, IH), 6.95(m, IH), 7.48(m, 4H), 7.70(m, IH)
Example 18: l-[4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl- carbony 1] benzoy 1] piperazine 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid
(1.5 g) was dissolved in methylene chloride (50 ml) and then, triethylamine (0.7 ml) was added and cooled. Pivaloyl chloride (0.58 ml) was added slowly to the solution at 0 ~ 5°C and the mixture was stirred at 5°C for 2 hours. With the addition of piperazine (0.9 g), the solution was stirred at 5 ~ 10 °C for 3 hours. The reaction mixture was washed wii water and aqueous sodium bicarbonate and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and further recrystallized using isopropanol and ether. The recrystallized product was filtered and dried to give 1.48 g (yield: 83%) of the desired compound as white crystal. m.p. : 175 ~ 176°C
Η-NMR(CDCb), ppm : δ 1.21(d, 6H), 2.51 (m, IH), 2.84(m, 2H), 3.03(m, 6H), 3.52(m, 5H), 3.80(m, 2H), 3.90(m, 2H), 4.13(m, IH),
6.80(m, IH), 6.93(m, IH), 7.47(m, 4H), 7.66(m, IH)
Example 19: 1 - [4- [1 - [3-(Isopropy lamino)-2-py ridy 1] piper azin-4-yl- carbonyl]benzoyl]-4-methylpiperazine 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid
(1.2 g) was dissolved in methylene chloride (40 ml) and then, triethylamine (0.6 ml) was added and cooled. Pivaloyl chloride (0.46 ml) was added slowly to the solution at 0 ~ 5°C and the mixture was stirred at 5°C for 2 hours. With the addition of triethylamine (0.6 ml) and 1-methylpiperazine (0.38 g), the reaction mixture was stirred at 5 °C for 2 hours and heated slowly to 20 °C and stirred for 30 minutes. The reaction mixture was washed with water and aqueous sodium bicarbonate and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with hexane and ether, and further recrystallized using ethyl acetate and isopropyl ether. The recrystallized product was filtered and dried to give 1.15 g
(yield: 78%) of the desired compound as white powder, m.p. : 158 ~ 160 °C
Η-NMR(CDC13), ppm : δ 1.20(d, 6H), 2.33(m, 5H), 2.54(m, 2H), 3.05(m, 4H),
3.47(m, 5H), 3.85(m, 4H), 4.12(m, IH), 6.82(m, IH), 6.90(m, IH), 7.45(m, 4H), 7.65(m, IH)
Example 20: 4-Ethyl-l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbony 1] benzoy 1] piperazine The desired compound was obtained by the same synthetic method as described in the Example 19. Yield: 85 % m.p. : 130 ~ 131 TJ Η-NMR(CDC13), ppm : δ 1.07(t, 3H), 1.20(d, 6H), 2.51 (m, 6H), 3.05(m, 4H),
3.51(m, 5H), 3.89(m, 4H), 4.13(m, IH), 6.81(m, IH), 6.93(m, IH), 7.46(m, 4H), 7.66(m, IH)
Example 21: 4-Cyclopentyl-l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4- y 1-carbony 1] benzoy 1] piperazine l-[4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoyl]piperazine (0.5 g) was dissolved in acetonitrile (25 ml) and then, N-methylmorpholine (0.17 ml) and cyclop ntyl bromide (0.3 ml) were added. The solution was heated to 65 ~ 75 °C and stirred for 20 hours. The solvent was concentrated under reduced pressure and then, the residue was dissolved in chloroform (40 ml). The solution was washed with water twice and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and hexane, and further recrystallized using ethanol and isopropyl ether. The recrystallized product was filtered and dried to give 0.41 g (yield: 71%) of the desired compound. m.p. : 181 ~ 182°C
Η-NMR(CDCl3), ppm : δ 1.22(d, 6H), 1.41 (m, 2H), 1.53(m, 2H), 1.69(m, IH),
1.85(m, 2H), 2.42(m, 2H), 2.57(m, 2H), 3.04(m, 4H), 3.43(m, 2H), 3.51(m, 3H), 3.81(m, 4H), 4.14(m, IH),
6.81(m, IH), 6.91(m, IH), 7.45(m, 4H), 7.66(m, IH)
Example 22: 4-(2-Hydroxyethyl)-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
By the same procedure as described in the example 19, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using l-(2-hydroxyethyl)piperazine. Then, the product was recrystallized using isopropanol and ether to give the desired compound.
Yield: 82 % m.p. : 148 ~ 149 °C
Η-NMR(CDC13), ppm : δ 1.23(d, 6H), 2.49(m, 2H), 2.62(m, 4H), 3.05(m, 4H), 3.52(m, 5H), 3.65(m, 2H), 3.84(m, 4H), 4.11(m, IH),
6.80(m, IH), 6.91 (m, IH), 7.45(m, 4H), 7.66(m, IH)
Example 23: 4-(3-Hydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine l-[4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoyl]piperazine (0.5 g) was dissolved in anhydrous ethanol (25 ml) and then, triethylamine (0.3 mi) and 3-bromo-l-propanol (0.5 g) were added. The solution was heated to reflux for 12 hours. The solvent was concentrated under reduced pressure and then, the residue was dissolved in chloroform (50 ml), and the solution was washed with water twice. Water
(40 ml), methanol (5 ml) and aqueous 10% sodium hydroxide (10 ml) were added to chloroform solution and the mixture was stirred for 1 hour. The separated organic layers were washed with water and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether, and further recrystallized using ethyl acetate and ether, filtered and dried to give 0.44 g (yield: 78%) of the desired compound as white crystal, m.p. : 129°C Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 1.76(m, 2H), 2.50(m, 2H), 2.68(m, 4H),
3.04(m, 4H), 3.51(m, 5H), 3.80(m, 6H), 4.12(m, IH), 6.80(m, IH), 6.91 (m, IH), 7.47(m, 4H), 7.65(m, IH)
Example 24: 4-[(2R)-3-Hydroxy-2-methylpropyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
The desired compound was obtained by the same synthetic method as described in the Example 23. Yield: 75 % Η-NMR(CDC13), ppm : δ 1.01(d, 3H), 1.20(d, 6H), 2.00(m, IH), 2.50(m, 2H),
2.67(m, 4H), 3.05(m, 4H), 3.51(m, 5H), 3.79(m, 6H), 4.11(m, IH), 6.81(m, IH), 6.91(m, IH), 7.45(m, 4H), 7.66(m, IH)
Example 25: 4-[(2S)-3-Hydroxy-2-methylpropyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
The desired compound was obtained by the same synthetic method as described in the Example 23. Yield: 72 % Η-NMR(CDC13), ppm : δ 1.02(d, 3H), 1.21(d, 6H), 2.01(m, IH), 2.50(m, 2H),
2.67(m, 4H), 3.06(m, 4H), 3.50(m, 5H), 3.79(m, 6H), 4.10(m, IH), 6.80(m, IH), 6.90(m, IH), 7.47(m, 4H), 7.66(m, IH)
Example 26: 4-(2,2-Dimethyl-3-hydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
The desired compound was obtained by the same synthetic method as described in the Example 23. Yield: 80 %
Η-NMR(CDC13), ppm : δ 1.04(s, 6H), 1.20(d, 6H), 2.51(m, 2H), 2.68(m, 4H),
3.06(m, 4H), 3.50(m, 5H), 3.79(m, 6H), 4.10(m, IH), 6.80(m, IH), 6.90(m, IH), 7.47(m, 4H), 7.66(m, IH)
Example 27: 4-(2,3-Dihydroxypropyl)-l-[4-[l-[3-(isopropylamino)-2- py ridyl] piperazin-4-y 1-carbony l]benzoyl] piperazine
By the same procedure as described in the example 23, synthesis was carried out starting with l-[4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoyl]piperazine and using 3-bromo-l,2-propanediol. Then, the product was recrystallized using isopropanol and isopropyl ether to give the desired compound. Yield: 71 % m.p. : 158°C Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 2.47(m, 2H), 2.70(m, 6H), 3.09(m, 4H),
3.51(m, 5H), 3.75(m, IH), 3.88(m, 6H), 4.13(m, IH), 6.81(m, IH), 6.91(m, IH), 7.48(m, 4H), 7.66(m, IH)
Example 28: 4-[2-(2-Hydroxyethoxy)ethyl]-l-[4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzoyl]piperazine
The desired compound was obtained by the same synthetic method as described in the Example 19. Yield: 80 % m.p. : 92 ~ 93 °C Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 2.55(m, 4H), 3.09(m, 4H), 3.52(m, 5H),
3.59(m, 4H), 3.69(m, 4H), 3.89(m, 4H), 4.12(m, IH), 6.80(m, IH), 6.91(m, IH), 7.43(m, 4H), 7.66(m, IH) Example 29: l-[4-[l-[3-(Ethylammo)-2-pyridyl]piperazin-4-yl- carbonyl]benzoyl]-4-(2-hydroxyethyl)piperazine
By the same procedure as described in the example 19, synthesis was carried out starting with 4-[l-[3-(ethylamino)-2-pyridyl]piperazin-4-yl- car bony l]benzoic acid and using l-(2-hydroxyethyl)piperazine. Then, the product was recrystallized using ethyl acetate and hexane to give the desired compound. Yield: 76 % m.p. : 152 ~ 153 °C Η-NMR(CDC13), ppm : δ 1.29(t, 3H), 2.51(m, 2H), 2.63(m, 4H), 3.12(m, 6H),
3.45(m, 4H), 3.70(m, 2H), 3.87(m, 4H), 4.18(m, IH), 6.92(m, IH), 6.97(m, IH), 7.46(m, 4H), 7.68(m, IH)
Example 30: l-[N-(l,l-Dimethyl-2-hydroxyethyl)carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid (1.5 g) was dissolved in methylene chloride (45 ml), and then triethylamine (0.73 ml) was added and cooled. Pivaloyl chloride (0.58 ml) was added slowly to the solution at 0 ~ 5 °C and the mixture was stirred at 5 °C for 2 hours. And then, pyridine (0.65 ml) and 2-amino-2-methyl-l-propanol (0.4 g) were added in order, the solution was stirred at 0 ~ 5°C for 2 hours and heated to 20 °C and stirred for 1 hour. The reaction mixture was washed with water twice and dried over anhydrous magnesium sulfate. Then, the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and further recrystallized using ethyl acetate and ether. The recrystallized product was filtered and dried to give
1.5 g (yield: 84%) of a desired compound. m.p. : 113 ~ 115 TJ Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 1.41(s, 6H), 3.10(m, 4H), 3.52(m, 3H),
3.68(s, 2H), 3.90(m, 2H), 4.14(s, IH), 6.31(s, IH), 6.85(m, IH), 6.96(m, IH), 7.45(m, 2H), 7.67(m, IH), 7.77(m, 2H)
Example 31: l-[N-[(lS)-2-Hydroxy-l -methy lethyl] carbamoy 1] -4- [1- [3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid methyl ester (1.8 g) and (S)-(+)-2-amino-l-propanol (0.71 g) were dissolved in methanol (30 ml) and heated to reflux for 12 hours. The reaction mixture was cooled and with the slow addition of excess of water at 40 °C to precipitate the crystals, the mixture was cooled again and stirred at 20 °C for 1 hour. Following with filtration and washing with water, the filtered solid was recrystallized using isopropanol and ether, filtered and dried to give 1.66 g (yield: 83%) of the desired compound. m.p. : 132 ~ 133 °C
Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 1.29(d, 3H), 3.05(m, 4H), 3.49(m, 3H),
3.63(m, IH), 3.78(m, IH), 3.89(m, 2H), 4.13(m, IH), 4.25(m, IH), 6.67(m, IH), 6.85(m, IH), 6.95(m, IH), 7.40(m, 2H), 7.66(m, IH), 7.78(m, 2H)
Example 32: l-[N-[(lR)-2-Hydroxy-l-methylethyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 31. Yield : 75 %
Η-NMR(CDC13), ppm : δ 1.20(d, 6H), 1.29(d, 3H), 3.05(m, 4H), 3.50(m, 3H),
3.63(m, IH), 3.78(m, IH), 3.90(m, 2H), 4.13(m, IH), 4.24(m, IH), 6.67(m, IH), 6.86(m, IH), 6.95(m, IH), 7.40(m, 2H), 7.66(m, IH), 7.79(m, 2H)
Example 33: l-[N-[(lS)-2-Hydroxy-l-(l-methylethyl)ethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene By the same procedure as described in the example 30, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using (S)-(+)-2-amino-3-methyl-l-butanol. Then, the product was recrystallized using ethanol and isopropyl ether to give a desired compound. Yield: 80 % m.p. : 82 ~ 83 °C
Η-NMR(CDCl3), ppm : δ 0.98(d, 6H), 1.21(d, 6H), 2.01(m, IH), 3.08(m, 4H),
3.53(m, 3H), 3.82(m, 2H), 3.93(m, 3H), 4.14(m, IH), 6.70(m, IH), 6.85(m, IH), 6.95(m, IH), 7.39(m, 2H), 7.66(m, IH), 7.77(m, 2H)
Example 34: l-[N-[(lR)-2-Hydroxy-l-(l-methylethyl)ethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 33. Yield: 72 % m.p. : 86 ~ 88 °C
Η-NMR(CDC13), ppm : δ 0.99(d, 6H), 1.21(d, 6H), 2.02(m, IH), 3.06(m, 4H),
3.51(m, 3H), 3.80(m, 2H), 3.92(m, 3H), 4.13(m, IH), 6.68(m, IH), 6.83(m, IH), 6.96(m, IH), 7.40(m, 2H),
7.65(m, IH), 7.78(m, 2H)
Example 35: l-[N-[(lS)-l-Ethyl-2-hydroxyethyl]carbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 31, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid methyl ester and usirg (S)-(+)-2-amino-l-butanol. Then, the product was recrystallized using acetonitrile and isopropyl ether to give the desired compound. Yield: 79 %
Η-NMR(CDC13), ppm : δ 0.97(t, 3H), 1.21(d, 6H), 1.73(m, IH), 1.85(m, IH),
3.06(m, 4H), 3.51(m, 3H), 3.81(m, 2H), 3.92(m, 2H), 4.11 (m, 2H), 6.69(m, IH), 6.84(m, H), 6.97(m, IH),
7.41(m, 2H), 7.65(m, IH), 7.79(m, 2H)
Example 36: l-[N-[(lR)-l-Ethyl-2-hydroxyethyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene The desired compound was obtained by the same synthetic method as described in the Example 35. Yield: 73 %
Η-NMR(CDC13), ppm : δ 0.98(t, 3H), 1.21(d, 6H), 1.75(m, IH), 1.84(m, IH),
3.05(m, 4H), 3.51(m, 3H), 3.80(m, 2H), 3.93(m, 2H), 4.11(m, 2H), 6.69(m, IH), 6.84(m, IH), 6.98(m, IH),
7.41(m, 2H), 7.65(m, IH), 7.80(m, 2H)
Example 37: l-[N-(l-Ethyl-2-hydroxyethyl)carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene The desired compound was obtained by the same synthetic method as described in the example 35. Yield: 84 % Η-NMR(CDC13), ppm : δ 0.98(t, 3H), 1.21(d, 6H), 1.76(m, IH), 1.84(m, IH), 3.06(m, 4H), 3.51(m, 3H), 3.81(m, 2H), 3.92(m, 2H), 4.11 (m, 2H), 6.69(m, IH), 6.84(m, IH), 6.97(m, IH), 7.40(m, 2H), 7.66(m, IH), 7.79(m, 2H)
Example 38: l-[N-[(lS)-l-(Cyclohexylmethyl)-2-hydroxyethyl]carbamoyl]-4-[l- [3-(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid (1.5 g) was dissolved in methylene chloride (60 ml) and then, triethylamine (0.7 ml) was added and cooled. Pivaloyl chloride ('0.58 ml) was added slowly to the solution at 0 ~ 5 °C and the mixture was stirred at 5 °C for 2 hours. And then triethylamine (1.7 ml) and (S)-(+)-2-amino-3-cyclohexyl-l-propanol hydrochloride (0.87 g) were added in order, the solution was stirred at 0 °C for 3 hours and heated slowly to 20 °C and stirred for 1 hour. The reaction mixture was washed with water twice and the solvent was concentrated under reduced pressure. The concentrated residue was recrystallized using isopropanol and ether. The recrystallized product was filtered and dried to give 2.07 g (yield: 80%) of the desired compound. m.p. : 139 ~ 140°C
Η-NMR(CDC13), ppm : δ 0.89-1.01 (m, 2H), 1.22(m, 9H), 1.34(m, IH), 1.45(m, 2H), 1.71(m, 4H), 1.81(m, IH), 3.10(m, 4H), 3.51(m,
3H), 3.61(m, IH), 3.76(m, IH), 3.89(m, 2H), 4.13(m, IH), 4.26(m, IH), 6.59(m, IH), 6.83(m, IH), 6.95(m, IH), 7.40(m, 2H), 7.67(m, IH), 7.77(m, 2H)
Example 39: 1 -[N-[(lS)-2-Hy droxy-1-phenylethyl] carbamoy 1] -4- [1- [3-
(isopropy lamino)-2-py ridyl] piperazin-4-y 1-carbony 1] benzene
By the same procedure as described in the example 30, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using (S)-(+)-2-amino-2-phenylethanol. Then, the product was recrystallized using ethanol and petroleum ether to give the desired compound.
Yield: 77 % m.p. : 93 ~ 95 °C
Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 3.10(m, 4H), 3.51(m, 3H), 3.88(m, 2H),
3.96(m, 2H), 4.14(m, IH), 5.20(m, IH), 6.84(m, IH), 6.94(m, IH), 7.31~7.39(m, 8H), 7.65(m, IH), 7.80(m, 2H)
Example 40: l-[N-[(lR)-2-Hydroxy-l-phenylethyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 39. Yield: 75 %
Η-NMR(CDC1 ), ppm : δ 1.20(d, 6H), 3.09(m, 4H), 3.50(m, 3H), 3.88(m, 2H),
3.96(m, 2H), 4.13(m, IH), 5.20(m, IH), 6.84(m, IH), 6.95(m, IH), 7.30~7.39(m, 8H), 7.65(m, IH), 7.80(m, IH)
Example 41: l-[N-[Bis(hydroxymethyl)methyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 31, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid methyl ester and usi g 2-amino-l,3-propanediol. Then, the product was recrystallized using ethyl acetate and ether to give the desired compound. Yield: 79 % m.p. : 147 ~ 149 °C Η-NMR(CDCl3), ppm : δ 1.21(d, 6H), 3.06(m, 4H), 3.49(m, 3H), 3.90(m, 6H),
4.11(m, 2H), 6.85(m, IH), 6.96(m, IH), 7.38(m, 3H), 7.65(m, IH), 7.80(m, 2H)
5 Example 42: l-[N-[l,l-Bis(hydroxymethyl)propyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 41. Yield: 82 % l o Η-NMR(CDC13), ppm : δ 0.99(t, 3H), 1.21(d, 6H), 1.91(m, 2H), 3.06(m, 4H),
3.50(m, 3H), 3.90(m, 6H), 4.11(m, IH), 6.86(m, IH), 6.95(m, IH), 7.38(m, 3H), 7.66(m, IH), 7.80(m, 2H)
Example 43 : 1 - [N- [(2S)-2-Hy droxy propyl] carbamoy 1] -4- [1 - [3-(isopropy lamino)- 15 2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 31, synthesis was carried out starting with 4-il-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid methyl ester and using (S)-(+)-l-amino-2-propanol. Then, the product was recrystallized using isopropanol and tetrahydrofuran to 20 give the desired compound. Yield: 81 % m.p. : 135 °C
Η-NMR(CDC1 ), ppm : δ 1.21(m, 6H), 1.29(d, 3H), 3.05(m, 4H), 3.50(m, 3H),
3.59(m, IH), 3.72(m, 2H), 3.90(m, 2H), 4.13(m, IH), 25 4.25(m, IH), 6.67(m, IH), 6.85(m, IH), 6.95(m, IH),
7.40(m, 2H), 7.66(m, IH), 7.78(m, 2H)
Example 44: l-[N-[(2R)-2-Hydroxypropyl]carbamoyl]-4-[l-[3-(isopropylamino)- 2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 43.
Yield: 74 % m.p. : 133 - 134 °C
Η-NMR(CDC1 ), ppm : δ 1.20(m, 6H), 1.29(d, 3H), 3.04(m, 4H), 3.50(m, 3H),
3.60(m, IH), 3.73(m, 2H), 3.91 (m, 2H), 4.11 (m, IH), 4.25(m, IH), 6.67(m, IH), 6.85(m, IH), 6.95(m, IH), 7.40(m, 2H), 7.66(m, IH), 7.78(m, 2H)
Example 45: 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N-
(2-methoxyethyl)carbamoyl]benzene
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid methyl ester (1.6 g) was dissolved in methanol (35 ml) and then, 2- methoxyethylamine (0.68 g) was added. And then, the reaction mixture was heated to reflux for 10 hours. The mixture was cooled, and after excess of water was added slowly to the solution at 35 ~ 40 °C to precipitate the crystals, the solution was slowly cooled again, stirred at 10 °C for 1 hour and filtered. The filtered solid was washed with a co-solvent (water:methanol = 4:1, v/v) and was recrystallized using isopropanol and ether, filtered and dried to give 1.39 g (yield: 78%) of the desired compound. m.p. : 120 ~ 121 °C
Η-NMR(CDC1 ), ppm : δ 1.23(d, 6H), 3.15(m, 4H), 3.38(s, 3H), 3.55(m, 5H),
3.64(m, 2H), 3.91(m, 2H), 6.55(m, IH), 6.90(m, IH), 6.99(m, IH), 7.49(m, 2H), 7.70(m, IH), 7.81 (m, 2H)
Example 46: l-[N,N-Bis(2-methoxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene
4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid (1.5 g) was dissolved in methylene chloride (45 ml) and then, triethylamine (0.7 ml) was added and cooled. Pivaloyl chloride (0.58 ml) was added slowly to the solution at 0 - 5°C and the mixture was stirred at 5°C for 2 hours. N,N-Diisopropylethylamine (0.8 ml) and bis(2-methoxyethyl)amine (0.6 g) were added in order, the solution was stirred at 0 ~ 5°C for 2 hours and heated slowly to 20 - 25 °C and stirred for 30 minutes. The reaction mixture was washed with water twice and with aqueous 5% sodium bicarbonate. Then, the solvent was dried over anhydrous sodium sulfate and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and further recrystallized using ethyl acetate and ether. The recrystallized product was filtered and dried to give
1.65 g (yield: 84%) of the desired compound. m.p. : 82 ~ 83 °C Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 3.08(m, 4H), 3.25(s, 3H), 3.36(m, 5H), 3.52(m, 5H), 3.64(m, 2H), 3.74(m, 2H), 3.90(m, 2H),
4.15(m, IH), 6.82(m, IH), 6.91 (m, IH), 7.44(m, 4H), 7.66(m, IH)
Example 47: 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N- (3-methoxy propy l)carbamoy 1] benzene
The desired compound was obtained by the same synthetic method as described in the Example 45. Yield: 75 %
Η-NMR(CDC1 ), ppm : δ 1.22(d, 6H), 1.80(m, 3H), 3.13(m, 4H), 3.39(s, 3H), 3.53(m, 5H), 3.63(m, 2H), 3.91(m, 2H), 6.55(m, IH),
6.90(m, IH), 6.96(m, IH), 7.49(m, 2H), 7.71(m, IH), 7.80(m, 2H) Example 48: l-[N-(2,2-Dimethoxyethyl)-N-methylcarbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 46, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using methylaminoacetaldehyde dimethyl acetal.
Then, the product was recrystallized using acetonitrile and ether to give the desired compound.
Yield : 80 %
Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 3.01(s, 3H), 3.14(m, 4H), 3.38(s, 3H), 3.41 (s, 3H), 3.51(m, 5H), 3.91 (m, 2H), 4.82(m, IH),
6.87(m, IH), 6.94(m, IH), 7.46(m, 4H), 7.67(m, IH)
Example 49: l-[N-(2,2-Diethoxyethyl)carbamoyl]-4-[l-[3-(isopropylamino)-2- pyridyl]piperazin-4-yl-carbonyl]benzene By the same procedure as described in the example 46, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using 2,2-diethoxyethylamine. Then, the product was recrystallized using ethanol and isopropyl ether to give the desired compound. Yield : 76 %
Η-NMR(CDC13), ppm : δ 1.22(m, 12H), 3.15(m, 4H), 3.50(m, 5H), 3.57(m, 2H),
3.80(m, 2H), 3.92(m, 2H), 4.85(m, IH), 6.87(m, IH), 6.93(m, IH), 7.45(m, 4H), 7.67(m, IH)
Example 50: l-[N-[(l,3-Dioxolan-2-yl)methyl]-N-methylcarbamoyl]-4-[l-[3- (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 46. Yield: 81 % m.p. : 102 ~ 104 °C
Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 3.12(m, 7H), 3.42(m, IH), 3.54(m, 3H),
3.72(m, IH), 3.90(m, 6H), 4.15(m, IH), 5.01(m, IH), 6.87(m, 2H), 7.46(m, 4H), 7.69(m, IH)
Example 51: 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N- [(tetrahydrofuran-2-yl)methyl]carbamoyl]benzene
By the same procedure as described in the example 45, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid methyl ester and using tetrahydrofurfurylamine. Then, the product was recrystallized using ethyl acetate and hexane to give the desired compound. Yield: 83 % m.p. : 146 ~ 147°C
Η-NMR(CDC1 ), ppm : δ 1.21(d, 6H), 1.61(m, IH), 1.94(m, 2H), 2.02(m, IH),
3.11(m, 4H), 3.33(m, IH), 3.52(m, 3H), 3.76(m, 2H), 3.86(m, 3H), 4.05(m, IH), 4.12(m, IH), 6.53(m, IH), 6.87(m, IH), 6.95(m, IH), 7.49(m, 2H), 7.68(m, IH), 7.81 (m, 2H)
Example 52: 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N- [[(2R)-tetrahydrofuran-2-yl]methyl]carbamoyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 51. Yield: 77 %
Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 1.60(m, IH), 1.93(m, 2H), 2.02(m, IH),
3.11(m, 4H), 3.31(m, IH), 3.51(m, 3H), 3.77(m, 2H), 3.86(m, 3H), 4.06(m, IH), 4.13(m, IH), 6.52(m, IH), 6.87(m, IH), 6.95(m, IH), 7.50(m, 2H), 7.68(m, IH), 7.82(m, 2H)
Example 53: 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N- [[(2S)-tetrahydrofuran-2-yl]methyl]carbamoyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 51. Yield: 79 % Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 1.61(m, IH), 1.93(m, 2H), 2.03(m, IH),
3.12(m, 4H), 3.32(m, IH), 3.52(m, 3H), 3.77(m, 2H), 3.86(m, 3H), 4.06(m, IH), 4.12(m, IH), 6.53(m, IH), 6.87(m, IH), 6.94(m, IH), 7.49(m, 2H), 7.68(m, IH), 7.81 (m, 2H)
Example 54: 4-[l-[3-(Isopropylamino)-2-pyridyl]piρerazin-4-yl-carbonyl]-l- (morpholin-4-yl-carbonyl)benzene
4- [1 - [3-(Isopr opy lamino)-2-py ridy 1] piperazin-4-y 1-carbony 1] benzoic acid (1.5 g) was dissolved in methylene chloride (45 ml) and then, triethylamine (0.7 ml) was added and cooled. Pivaloyl chloride (0.58 ml) was added slowly to the solution at 0 - 5°C and the mixture was stirred at 5°C for 2 hours. After the slow addition of morpholine (0.91 g), the solution was stirred at 0 - 5°C for 3 hours. The reaction mixture was washed with water twice and with aqueous 1% acetic acid and 5% sodium bicarbonate one time each. Then, the solvent was dried over anhydrous sodium sulfate and the solvent was concentrated under reduced pressure. The concentrated residue was crystallized by treatment with ether and further recrystallized using methanol and hexane. The recrystallized product was filtered and dried to give 1.52 g (yield: 85%) of the desired compound. m.p. : 139tJ
Η-NMR(CDC1 ), ppm : δ 1.23(d, 6H), 3.10(m, 4H), 3.41(m, 2H), 3.53(m, 5H),
3.77(m, 4H), 3.90(m, 2H), 4.14(m, IH), 6.85(m, IH), 6.96(m, IH), 7.48(m, 4H), 7.67(m, IH)
Example 55: 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l- (thiomorpholin-4-yl-carbonyl)benzene
The desired compound was obtained by the same synthetic method as described in the Example 54. Yield: 76 % m.p. : 163 ~ 164 °C
Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 2.53(m, 2H), 2.72(m, 2H), 3.10(m, 4H),
3.52(m, 3H), 3.63(m, 2H), 3.91(m, 2H), 4.01(m, 2H), 4.14(m, IH), 6.85(m, IH), 6.93(m, IH), 7.41 (m, 2H),
7.46(m, 2H), 7.67(m, IH)
Example 56 : 4- [1 - [3-(Isopropy lamino)-2-py ridy 1] piperazin-4-y 1-carbony 1] -1 - [N- [2-(morpholin-4-yl)ethyl]carbamoyl]benzene 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzoic acid methyl ester (1.2 g) was dissolved in a co-solvent of ethanol (10 ml) and acetonitrile (20 ml), and 4-(2-aminoethyl)morpholine (0.82 g) was added. The reaction mixture was heated to reflux for 15 hours and cooled. After excess of water was added to the solution at 30 "C to precipitate the crystals, the solution was stirred for 1 hour. Then, the solution was again cooled slowly, stirred at 10 - 15 °C for 2 hours and filtered. The filtered crystal was washed with preheated water(40°C) and was recrystallized using isopropanol and ether, filtered and dried to give 1.22 g (yield: 81%) of the desired compound, m.p. : 114 ~ 116°C
Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 2.59(m, 4H), 2.68(m, 2H), 3.04(m, 4H),
3.57(m, 5H), 3.77(m, 4H), 3.90(m, 2H), 4.12(m, IH), 6.81(m, IH), 6.92(m, IH), 7.10(m, IH), 7.48(m, 2H),
7.65(m, IH), 7.85(m, 2H)
Example 57 : 4-[l-[3-(Isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]-l-[N-
[3-(morpholin-4-yl)propyl]carbamoyl]benzene The desired compound was obtained by the same synthetic method as described in the Example 56.
Yield : 74 % m.p. : 103°C
Η-NMR(CDC13), ppm : δ 1.21(d, 6H), 1.85(m, 2H), 2.62(m, 6H), 3.05(m, 4H), 3.53(m, 5H), 3.75(m, 4H), 3.91(m, 2H), 4.12(m, IH),
6.81(m, IH), 6.92(m, IH), 7.51(m, 2H), 7.66(m, IH), 7.87(m, 2H), 8.13(m, IH)
Example 58 : 4- [1 - [3-(Isopropy lamino)-2-py r idy 1] piperazin-4-y 1-carbony 1] -1 - [N- [2-(piperidin-l-yl)ethyl]carbamoyl]benzene
By the same procedure as described in the example 56, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid methyl ester and using l-(2-aminoethyl)piperidine.
Then, the product was recrystallized using acetonitrile and hexane to give the desired compound.
Yield: 70 % m.p. : 106 ~ 107°C
Η-NMR(CDCl3), ppm : δ 1.22(d, 6H), 1.46(m, 2H), 1.61(m, 4H), 2.47(m, 4H), 2.58(m, 2H), 3.06(m, 4H), 3.54(m, 5H), 3.90(m, 2H), 4.12(m, IH), 6.81(m, IH), 6.91(m, IH), 7.14(m, IH), 7.48(m, 2H), 7.66( , IH), 7.83(m, 2H)
5 Example 59: l-[N-[2-(Dimethylamino)ethyl]carbamoyl]-4-[l-[3-
(isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 45, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid methyl ester and using N,N-dimethylethylenediamine. l o Then, the product was recrystallized using ethanol and isopropyl ether to give the desired compound. Yield: 79 % m.p. : 133 °C
Η-NMR(CDC13), ppm : δ 1.22(d, 6H), 2.31(s, 6H), 2.57(m, 2H), 3.09(m, 4H), 15 3.53(m, 5H), 3.91(m, 2H), 4.13(m, IH), 6.80(m, IH),
6.91(m, IH), 7.04(m, IH), 7.48(m, 2H), 7.66(m, IH), 7.86(m, 2H)
Example 60: l-[N-[2-(Dimethylamino)ethyl]-N-methylcarbamoyl]-4-[l-[3- 20 (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
By the same procedure as described in the example 46, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid and using N,N,N' -trimethylethylenediamine. Then, the product was recrystallized using isopropanol and ether to give the desired 25 compound. Yield: 80 %
Η-NMR(CDCl3), ppm : δ 1.22(d, 6H), 2.31(s, 6H), 2.58(m, 2H), 3.01(s, 3H),
3.10(m, 4H), 3.53(m, 5H), 3.90(m, 2H), 4.12(m, IH), 6.80(m, IH), 6.92(m, IH), 7.48(m, 2H), 7.67(m, IH), 7.86(m, 2H)
Example 61: l-[N-[2-(Dimethylamino)ethyl]-N-ethylcarbamoyl]-4-[l-[3- 5 (isopropylamino)-2-pyridyl]piperazin-4-yl-carbonyl]benzene
The desired compound was obtained by the same synthetic method as described in the Example 60. Yield: 74 %
Η-NMR(CDC13), ppm : δ 1.10(t, 3H), 1.22(d, 6H), 2.30(s, 6H), 2.59(m, 2H), l o 3.11(m, 4H), 3.52(m, 7H), 3.91(m, 2H), 4.12(m, IH),
6.81(m, IH), 6.92(m, IH), 7.49(m, 2H), 7.67(m, IH), 7.87(m, 2H)
Example 62: l-[N-[2-(Diethylamino)ethyl]carbamoyl]-4-[l-[3-(isopropylamino)- 15 2-py ridyl] piperazin-4-y 1-carbony ljbenzene
By the same procedure as described in the example 45, synthesis was carried out starting with 4-[l-[3-(isopropylamino)-2-pyridyl]piperazin-4-yl- carbonyl]benzoic acid methyl ester and using N,N-diethylethylenediamine. Then, the product was recrystallized using isopropanol and hexane to give the 20 desired compound. Yield: 76 %
Η-NMR(CDC13), ppm : δ 1.02(t, 6H), 1.22(d, 6H), 2.60(m, 6H), 3.11 (m, 4H),
3.51(m, 5H), 3.90(m, 2H), 4.13(m, IH), 6.18(m, IH), 6.92(m, IH), 7.05(m, IH), 7.49(m, 2H), 7.67(m, IH), 25 7.87(m, 2H)
Hereinafter, the anti-HBV activity of terephthalamide derivatives of the above formula 1 according to the present invention was evaluated in vitro. The evaluation procedure and results were described in the following Experiments 1 to 4.
Experiment 1 : The inhibitory activity against HBN polymerase in vitro.
Recently, the inventors of the present invention have produced a recombinant HBN polymerase that is expressed from E.coli transformant, measured its enzyme activity and filed patent applications thereof [Korean Patent Application Νos. 94-3918, 96-33998 and 96-63255].
The inventiors have established a method of measuring the reverse transcriptase activity of HBN polymerase in vitro. The fundamental principle is the same as the ELISA method, and after reacting the substrate with biotin- and DIG-modified nucleotide, a method of recognizing the polymerized substrate as anti-DIG antibody with peroxidase was used. 20/ I of HBV polymerase, 20/ΛC of reaction mixture and 20//4. of test compound were mixed and reacted at 14 - 30 °C for 18 - 24 hours. Then, the inhibitory effect of test compound against reverse trascriptase activity in the HBV polymerase was examined, compared with the results of control tests without the test compound. The inhibitory activity of each test compound is shown in the following Table 1.
Table 1. The inhibitory effects of reverse transcriptase(RT) enzyme activity of hepatitis B virus(HBV)
Figure imgf000057_0001
Table 1. (Continued)
Figure imgf000058_0001
Table 1. (Continue)
Figure imgf000059_0001
Table 1. (Continued)
Figure imgf000060_0001
Experiment 2 : The inhibitory effects against RNase H activity of HBV polymerase.
1) Expression of the RNase H domain derived from human HBV polymerase
E.coli NM 522 was transformed by the expression vector pMRH respectively and the transformants were cultured in LB medium at 37 °C, overnight. These growing cultures were diluted 1 : 100, inoculated into a glucose rich medium and incubated until OD600 reached 0.5. Then IPTG
(isopropylthiogalactoside) was added into the medium of which the final concentration was 0.5 mM. The above growing cultures were incubated again at 20 °C for 16 hours and the RNase H domain was expressed.
The above cultured broth was centrifuged for 10 minutes at 3,000 rpm and the cell pellet was washed with 10 ml of TNE column buffer (10 mN Tris-Cl, pH 8.0, 200 mM NaCl, 1 mM EDTA), and resuspended in 10 ml of TNE column buffer. The cells were freezed and thawed -i times repeatedly, and then disrupted by sonication for 10 seconds 3 times. The crude extract prepared in the above process was centrifuged for 30 minutes at 13,000 rpm, 4 °C and the supernatant was separated. The above process was repeated 2 times and then the supernatant passed the amylose resin. The resin was washed by using column buffer with 50 times of resin volume, and the RNase H domain was eluted by using buffer containing 10 mM maltose.
In addition, the RNase H domain produced from the expression vector pMRH was purified by using histidine tag affinity column, because RNase H has a histidine tag at the C-terminus. The resin (Ni-NT A, QIAGEN) used in the histidine tag affinity column was activated by using sonication buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride) and 4 - 5 ml of the activated resin was charged in the glass tube whose diameter was about 1 cm. The protein sample obtained from above description passed the resin at the 0.1 ml/ min flow rate and the column was washed by using washing buffer with the 100 - 200 times volume of protein sample (50 mM sodium phosphate, pH 6.0, 300 mM sodium chloride, 10% glycerol). The recombinant protein was eluted by washing the column with concentration gradient of 0.01 - 0.5 M imidazole. As a result, the active RNase H domain was separated from the histidine tag affinity column at 30 mM concentration of imidazole. The purified
RNase H domain was mixed with 50% glycerol for storage at -20 °C after the removal of imidazole from it and employed for the screening of HBV inhibitors. 2) Preparation of the substrate of the RNase H enzyme
In order to identify the RNase H activity, RNA/ DNA complex which can be used as a substrate of the RNase H enzyme was prepared by performing in vitro transcription with E coli M.
As discussed in the above, the compound(l) according to the present invention, and its pharmaceutically acceptable salts are effective as active ingredients of inhibiting the proliferation of various viruses including HBV and HIV in that without any cytotoxicity.
3) Screening of active inhibitors against RNase H
The RNase H activity was measured by using recombinant Rnase H enzyme and radiolabled RNA/ DNA hybrid. In order to measure the
RNase H activity, 1 g of RNase H enzyme and test compound were mixed with buffer solution containing 40 mM Tris-Cl (pH 8.0), 4 mM magnesium chloride, 40 mM potassium chloride and 2 mM DTT. The mixture was pretreated on ice for 10 minutes. After pretreatment is completed,
RNA/ DNA hybrid was added to incubate at 37 °C for 3 hours. After the reaction was stopped, 7.5 M ammonium acetate in a volume of 1/2 and ethanol in a 3-fold volume were added. The above reaction mixture was incubated at -20 °C for more than 2 hours and centrifuged for 15 minutes at 4°C, 13,000 rpm. The supernatant was obtained and the radioactive signal of supernatant was measured by scintillation counter.
As a control, water was added instead of test compound and the inhibitory activity was calculated to compare with the control, when the radioactivity intensity on each test compound, was obtained. The inhibitory activity of each test compound is shown in the following table 2. Table 2. The inhibitory effects of RNase H enzyme activity of hepatitis B virus(HBV) polymerization enzyme.
Figure imgf000063_0001
Table 2. (Continued)
Figure imgf000064_0001
Experiment 3 : The in vitro inhibition test against HIV reverse transcriptase
The inhibitory activity in vitro was measured using a non-radioactive reverse transcriptase assay Kit (Boehringer Mannheim).
At first, 20/ ,(40ng) HIV-RT was added to the wells coated with streptavidin and with the addition of 20μJl, reaction mixture containing template/ primer hybrid poly(A)/oligo(dT)ιs and DIG-(digoxigenin)-dUTP, biotin-dUTP and TTP, 20 μi test compound was added and reacted at 37 °C for 1 hour. The control without test compound was used for the comparison of related activity. Since DNA containing nucleotide labeled with digoxigenin and biotine was prepared by the action of HIV-RT, it was combined with streptavidin coated at the bottom of the wells. After the reaction was completed, remaining impurities were removed by washing each well with 250/z£ buffer solution (pH 7.0) for 30 seconds 5 times and with the addition of 200 μJl, anti-DIG-POD antibody, the mixture was reacted at 37 °C for 1 hour. For the removal of remaining impurities again, the reacting solution was washed with a buffer solution and with the addition of 200/ztf ABTS™ each, a substrate of POD(peroxidase), the solution was reacted at room temperature for 30 minutes. The absorbance was read by ELISA reader at
405nm for the assay of reverse transcriptase activity and its inhibition activity. The results of test compound are shown in the following table 3.
Table 3. The inhibitory effects against reverse transcriptase (HIV-RT) of AIDS virus
Figure imgf000066_0001
Table 3. (Continued)
Figure imgf000067_0001
Table 3. (Continued)
Figure imgf000068_0001
Table 3. (Continued)
Figure imgf000069_0001
Experiment 4 : Cytotoxicity
The cytotoxicity test was carried out using HepG2 cells in vitro. As a result, terephthalamide derivatives of the above formula 1 according to the present invention, and its pharmaceutically acceptable salts proven not to have cytotoxicity with CCso≥200μM. As discussed in the above, the compounds of the above formula 1 according to the present invention, and its pharmaceutically acceptable salts are effective as active ingredients of inhibiting the proliferation of various viruses including HBV and HIV in that without any cytotoxicity.

Claims

What is claimed is:
1. A terephthalamide derivative of the following formula 1:
Figure imgf000070_0001
wherein:
Ri and R2 represent independently one selected from hydrogen atom; phenyl group; benzyl group; O-Ce alkyl group; substituted Ci~C alkyl group in which one substituent selected from di(Cι~C alkyl)amino, acetylamino group and heterocycles; Cι~Cs hydroxyalkyl group; substituted Cι~C hydroxyalkyl group in which one or two substituents selected from phenyl, benzyl, Cι~C hydroxyalkyl and Cι~C7 alkyl group; C2~Cό alkoxyalkyl group; di(C2~C6 alkoxy)alkyl group; C2~Cs (hydroxyalkoxy)alkyl group; with the proviso that Ri and R2 do not simultaneously represent hydrogen atom; in case where either Ri or R2 is hydrogen atom, the stereospecificity of (R)- or (S)-type may be represented; further, Ri and R2 may be combined with one or two hetero atoms selected from nitrogen, oxygen and sulfur to form five or six membered heterocycles, wherein the heterocycles may be substituted with one substituent selected from Cι~Cs alkyl, C3~C6 cycloalkyl, C3~C5 (hydroxyalkoxy)alkyl, C ~Cs hydroxyalkyl, 0~C3 alkyl-substituted Cι~C hydroxyalkyl, Q-Q dihydroxyalkyl and Cι~C3 alkyl-substituted Cι~C dihydroxyalkyl group; R3 represents Cι~G- alkyl group; further, the above mentioned alkyl group includes straight or branched alkyl group or cycloalkyl group; or its pharmaceutically acceptable salt.
2. The terephthalamide derivative according to claim 1, wherein one between Ri and R2 is hydrogen atom and the other is C1M3 alkoxy Cι~C alkyl group; di(C2~Cs alkoxy) Cι~C alkyl group; l,3-dioxolan-2-yl- methyl group; tetrahydrofuran-2-yl-methyl group; 2-(morpholin-4- yl)ethyl group; 3-(morpholin-4-yl)propyl group; 2-(piperidin-l-yl)ethyl group; di(Cι~C3 alkyljamino Q-C3 alkyl group; 2-(acetylamino)ethyl group; 2-hydroxyethyl group; or substituted 2-hydroxyethyl group with one or two substituents selected from phenyl group, benzyl group, Cι~C3 hydroxyalkyl group and O-Cs alkyl group.
3. The terephthalamide derivative according to claim 1, wherein one between Ri and R2 is Cι~C3 alkyl group and the other is di(0~C3 alkoxy) C2~C3 alkyl group; l,3-dioxolan-2-yl-methyl group; tetrahydrofuran-2-yl- methyl group; 2-(morpholin-4-yl)ethyl group; 3-(morpholin-4-yl)propyl group; 2-(piperidin-l-yl) ethyl group; 2-hydroxyethyl group; di(Cι~C3 alkyl)amino Ct~C3 alkyl group; or 2-(ace yk'.mino)ethyl group.
4. The terephthalamide derivative according to claim 1, wherein said Ri and R2 are simultaneously Cι~C3 alkyl group, hy droxy ethyl, or 2- hy droxy propyl.
5. The terephthalamide derivative according to claim 1, wherein said Ri and R2 are combined with one or two hetero atoms selected from nitrogen, oxygen and sulfur to form a heterocycle selected from morpholine, thiomorpholine, pyrrolidine, piperidine and piperazine ring.
The terephthalamide derivative according to claim 5, wherein nitrogen atom at 4-position of said piperazine ring is substituted with hydrogen atom, Ci-Cs alkyl group, C3~C6 cycloalkyl group, C2~Cs hydroxyalkyl group, C2~C dihydroxyalkyl group, C3~Cs (hy droxy alkoxy) alkyl group, Ci~C3 alkyl-substituted Q~C hydroxyalkyl group, (2R)-3-hydroxy-2- methylpropyl group or (2S)-3-hydroxy-2-methylpropyl group.
A pharmaceutical composition containing terephthalamide derivative of the following formula 1, or its pharmaceutically acceptable salts as an active ingredient.
Figure imgf000072_0001
Wherein: Ri, R2 and R3 are the same as defined in claim 1, respectively.
An antiviral agent comprising terephthalamide derivative of the following formula 1, or its pharmaceutically acceptable salts as an active ingredient.
Figure imgf000073_0001
Wherein: Ri, R2 and R3 are the same as defined in claim 1, respectively.
9. The antiviral agent according to claim 8, wherein said virus represents hepatitis B virus(HBN) or human immunodeficiency virus (HIN).
10. A process for preparing terephthalamide derivatives of the following formula 1, comprising steps of reacting a compound of the following formula 2 and acid chloride to form an acid anhydride; and then reacting the intermediate with an amine compound of the following formula 3.
Figure imgf000073_0002
Figure imgf000074_0001
Wherein: Ri, R2 and R3 are the same as defined in claim 1, respectively.
11. A process for preparing terephthalamide derivatives of the following formula 1, comprising nucleophilic substitution of a compound of the following formula 4 with an amine compound of the following formula 3.
Figure imgf000074_0002
Figure imgf000074_0003
Figure imgf000074_0004
Wherein: Ri, R2 and R3 are the same as defined in claim 1, respectively.
12. A process for preparing terephthalamide derivatives of the following formula lb, comprising reaction of piperazine derivatives of the following formula la and halogen compound of the following formula 7 in the presence of tertiary organic base.
Figure imgf000075_0001
Figure imgf000075_0002
Figure imgf000075_0003
Wherein:
R3 is the same as defined in claim 1;
R represents hydrogen atom, Cι~Cs alkyl group, C3~C6 cycloalkyl group, C2~C5 hydroxyalkyl group, C2~Gι dihydroxyalkyl group, C3M5 (hydroxyalkoxy)alkyl group, or Cι~C3 alkyl-substituted C ~C hydroxyalkyl group; and
X represents halogen atom.
13. A process for preparing terephthalamide derivative of the following formula 2, comprising steps of reaction of mono-methyl terephthalate of the formula 9 and acid chloride to form an acid anhydride; then, the reaction mixture is further reacted with pyridylpiperazine derivative of the formula 8, to obtain terephthalic acid ester derivative including nitropyridyl group of the following formula 10; reduction of the compound of the formula 10 to give the derivative of the formula 11 including aminopyridyl group; reductive alkylation of the derivatives of the formula 11 with acetone or acetaldehyde in the presence of a selective reducing agent under acidic conditions to form terephthalic acid ester derivative of the formula 4; and hydrolysis of terephthalic acid ester derivative of the formula 4.
Figure imgf000076_0001
( 9 )
Figure imgf000076_0002
Figure imgf000077_0001
Figure imgf000077_0002
Figure imgf000077_0003
Figure imgf000077_0004
Wherein: R3 is the same as defined in claim 1.
PCT/KR1997/000183 1997-05-27 1997-09-30 Novel terephthalamide derivatives WO1998054140A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44733/97A AU731638B2 (en) 1997-05-27 1997-09-30 Novel terephthalamide derivatives

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR1019970020958A KR19980085016A (en) 1997-05-27 1997-05-27 New Terephthalate Amide Derivatives
KR19970020957 1997-05-27
KR1997/20958 1997-05-27
KR1997/20957 1997-05-27
KR1019970023289A KR19990000415A (en) 1997-06-05 1997-06-05 New Terephthalate Amide Derivatives
KR1997/23289 1997-06-05
KR1997/36589 1997-07-31
KR1019970036589A KR100491100B1 (en) 1997-05-27 1997-07-31 Terephthalate Amide Derivatives

Publications (1)

Publication Number Publication Date
WO1998054140A1 true WO1998054140A1 (en) 1998-12-03

Family

ID=27483204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1997/000183 WO1998054140A1 (en) 1997-05-27 1997-09-30 Novel terephthalamide derivatives

Country Status (4)

Country Link
US (1) US5922871A (en)
CN (1) CN1254334A (en)
AU (1) AU731638B2 (en)
WO (1) WO1998054140A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064430A1 (en) * 1999-04-23 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Apoptosis inhibitors
WO2000064859A1 (en) * 1999-04-21 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Amide derivatives
US6306860B1 (en) 1998-05-13 2001-10-23 Dong Wha Pharm. Inc. Co., Ltd. 2,5-pyridinedicarboxylic acid derivatives
KR100420616B1 (en) * 1996-12-26 2004-05-17 동화약품공업주식회사 Novel terephthalamide derivatives
US6743795B1 (en) 1999-11-27 2004-06-01 Dong Wha Pharm. Ind. Co. Ltd. 3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives
US6762189B1 (en) 1999-11-27 2004-07-13 Dong Wha Pharm. Ind. Co., Ltd. 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives
US10595527B2 (en) 2017-12-12 2020-03-24 International Business Machines Corporation Antimicrobial polymers capable of supramolecular assembly
US10653142B2 (en) 2017-12-12 2020-05-19 International Business Machines Corporation Polymers with antimicrobial functionalities
US10667514B2 (en) 2017-12-12 2020-06-02 International Business Machines Corporation Antimicrobial ionene compositions with a variety of functional groups
US10687528B2 (en) 2017-12-12 2020-06-23 International Business Machines Corporation Antimicrobial polymers with enhanced functionalities
US10687530B2 (en) 2017-12-12 2020-06-23 International Business Machines Corporation Hydrophilic polymers with antimicrobial functionalities
US10743537B2 (en) 2017-12-12 2020-08-18 International Business Machines Corporation Monomer compositions with antimicrobial functionality
US10836864B2 (en) 2017-12-12 2020-11-17 International Business Machines Corporation Chemical compositions with antimicrobial functionality

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440389B (en) * 2018-05-07 2020-05-29 山东大学 3,4,5-Trihydroxybenzoic acid derivatives and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009849A1 (en) * 1989-12-28 1991-07-11 The Upjohn Company Diaromatic substituted anti-aids compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
US5599930A (en) * 1991-07-03 1997-02-04 The Upjohn Company Substituted indoles as anti-AIDS pharmaceuticals
DE4210942A1 (en) * 1992-04-02 1993-10-07 Bayer Ag 7-Oxo-7H-pyrido [1,2,3-d, e] [1,4] benzoxacin-6-carboxylic acids and esters
DE4210941A1 (en) * 1992-04-02 1993-10-07 Bayer Ag New 9-fluoro-7.oxo-7H-pyrido [1,2,3-d, e] [1,4] benzoxacin-6-carboxylic acids and esters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009849A1 (en) * 1989-12-28 1991-07-11 The Upjohn Company Diaromatic substituted anti-aids compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 115, No. 25, 23 December 1991, (Columbus, Ohio, USA), page 33, Abstract No. 270053y, ROMERO D.L. et al., "Non-Nucleoside Reverse Transcriptase Inhibitors that Potently and Specifically Block Human Immunodeficiency Virus Type 1 Replication"; & PROC. NATL. ACAD. SCI. USA, 1991, 88(19), 8806-10, (Eng). *
CHEMICAL ABSTRACTS, Vol. 120, No. 17, 25 April 1994, (Columbus, Ohio, USA), page 27, Abstract No. 207980m, ROMERO D.L. et al., "Discovery, Synthesis and Bioactivity of Bis(Heteroaryl)Piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors"; & J. MED. CHEM., 1994, 37(7), 999-1014, (Eng). *
CHEMICAL ABSTRACTS, Vol. 124, No. 15, 08 April 1996, (Columbus, Ohio, USA), page 1077, Abstract No. 202849y, ISLAM I. et al., "Synthesis and Antiviral Activity of[2-[[4-[3-[(1-Methylethyl)Amino]-2-Pyridy l]-1-Piperazinyl]Carbonyl]-1H-Indol-5-Yl](B HAP) Acylsphinogosine HIV Reverse Transcriptase Inhibitors"; & BIOORG. CHEM., *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100420616B1 (en) * 1996-12-26 2004-05-17 동화약품공업주식회사 Novel terephthalamide derivatives
US6306860B1 (en) 1998-05-13 2001-10-23 Dong Wha Pharm. Inc. Co., Ltd. 2,5-pyridinedicarboxylic acid derivatives
WO2000064859A1 (en) * 1999-04-21 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Amide derivatives
WO2000064430A1 (en) * 1999-04-23 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Apoptosis inhibitors
US6743795B1 (en) 1999-11-27 2004-06-01 Dong Wha Pharm. Ind. Co. Ltd. 3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives
US6762189B1 (en) 1999-11-27 2004-07-13 Dong Wha Pharm. Ind. Co., Ltd. 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives
US10667514B2 (en) 2017-12-12 2020-06-02 International Business Machines Corporation Antimicrobial ionene compositions with a variety of functional groups
US10653142B2 (en) 2017-12-12 2020-05-19 International Business Machines Corporation Polymers with antimicrobial functionalities
US10595527B2 (en) 2017-12-12 2020-03-24 International Business Machines Corporation Antimicrobial polymers capable of supramolecular assembly
US10687528B2 (en) 2017-12-12 2020-06-23 International Business Machines Corporation Antimicrobial polymers with enhanced functionalities
US10687530B2 (en) 2017-12-12 2020-06-23 International Business Machines Corporation Hydrophilic polymers with antimicrobial functionalities
US10743537B2 (en) 2017-12-12 2020-08-18 International Business Machines Corporation Monomer compositions with antimicrobial functionality
US10836864B2 (en) 2017-12-12 2020-11-17 International Business Machines Corporation Chemical compositions with antimicrobial functionality
US11006628B2 (en) 2017-12-12 2021-05-18 International Business Machines Corporation Antimicrobial polymers capable of supramolecular assembly
US11058110B2 (en) 2017-12-12 2021-07-13 International Business Machines Corporation Polymers with antimicrobial functionalities
US11525036B2 (en) 2017-12-12 2022-12-13 International Business Machines Corporation Chemical compositions with antimicrobial functionality
US11617367B2 (en) 2017-12-12 2023-04-04 International Business Machines Corporation Antimicrobial polymers capable of supramolecular assembly
US11723363B2 (en) 2017-12-12 2023-08-15 International Business Machines Corporation Polymers with antimicrobial functionalities

Also Published As

Publication number Publication date
AU4473397A (en) 1998-12-30
US5922871A (en) 1999-07-13
CN1254334A (en) 2000-05-24
AU731638B2 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
US5519016A (en) Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-HIV agent
KR100798579B1 (en) Novel methoxy-1,3,5-triazine derivatives and pharmaceutical compositions comprising the same
US5616606A (en) Oligopeptide antiretroviral agents
WO1998054140A1 (en) Novel terephthalamide derivatives
WO2003002518A1 (en) Novel 2,4-difluorobenzamide derivatives as antiviral agents
WO2000061556A1 (en) Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
KR100579792B1 (en) Novel 2,5-pyridinedicarboxylic acid derivatives
US6608058B2 (en) 6-methylnicotinamide derivatives as antiviral agents
US20220041577A1 (en) Heterocyclic Compound as CDK-HDAC Double-Channel Inhibitor
MXPA04009114A (en) 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same.
US4578465A (en) Phenyliperazine derivatives
JPWO2004014873A1 (en) 4-Substituted quinazoline-8-carboxylic acid amide derivatives and their pharmacologically acceptable addition salts
JP2003506442A (en) Novel tryptase inhibitor
KR100566194B1 (en) Novel 3-nitropyridine derivatives and pharmaceutical compositions comprising the same
US6743795B1 (en) 3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives
WO2001044195A1 (en) Heterocycle derivatives and drugs
JPH08183775A (en) Trifluoromethylquinolinecarboxylic acid derivetive
KR100609490B1 (en) 6-methylnicotinamide derivatives useful as antiviral agents
KR100420616B1 (en) Novel terephthalamide derivatives
KR100566189B1 (en) Novel 5-pyrimidinecarboxamide derivatives and pharmaceutical compositions comprising the same
KR100661081B1 (en) 6-methylnicotinamide derivatives useful as antiviral agents
KR100491100B1 (en) Terephthalate Amide Derivatives
JP3805677B2 (en) Novel 5-pyrimidinecarboxamide derivatives and pharmaceutical compositions containing the derivatives
JP3249346B2 (en) 1,4-dihydropyridines
JPS60208971A (en) Novel oxazole derivative

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97182212.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref document number: 1999500502

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA